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ABSTRACT
Stabilization of the Cardiac Nervous System During Cardiac Stress Induces Cardioprotection
by
David D. Gibbons

The cardiac nervous system consists of nested reflex feedback loops that interact to regulate regional
heart function. Cardiac disease affects multiple components of the cardiac nervous system and the
myocytes themselves. This study aims to determine: 1) how select components of the cardiac
nervous system respond to acute cardiac stress, including myocardial ischemia (MI) and induced
neural imbalance leading to cardiac electrical instability, and 2) how neuromodulation can affect
neural-myocyte interactions to induce cardioprotection. Thoracic spinal cord stimulation (SCS) is
recognized for its anti-anginal effects and ability to reduce apoptosis in response to acute MI,
primarily via modulation of adrenergic efferent systems. The data presented here suggest that
cervical SCS exerts similar cardioprotective effects in response to MI, but in contradistinction to
thoracic SCS, uses both adrenergic and cholinergic efferent mechanisms to stabilize cardiomyocytes
and the arrhythmogenic potential. SCS potentially can use efferent and/or anti-dromically activated
cardiac afferents to mediate its cardioprotection. Thoracic SCS mitigates the MI-induced activation
of both nodose and dorsal root ganglia cardiac-related afferents, doing so without antidromic
activation of the primary cardiac afferents. Instead, thoracic SCS acts through altering the cardiac
milieu thereby secondarily affecting the primary afferent sensory transduction. In response to
cardiac stressors, reflex activation of efferent activity modifies mechanical and electrical functions of
the heart. Excessive activation of neuronal input to the cardiac nervous system can induce
arrhythmias. Stimulation of intrathoracic mediastinal nerves directly activates subpopulations of
intrinsic cardiac neurons, thereby inducing atrial arrhythmias. Neuromodulation, either thoracic SCS
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or hexamethonium, suppressed mediastinal nerve stimulation (MSNS)-induced activation of intrinsic
cardiac neurons and correspondingly reduced the arrhythmogenic potential. SCS exerted its
stabilizing effects on neural processing and subsequent effects on atrial electrical function by
selectively targeting local circuit neurons within the intrinsic cardiac nervous system. Together these
data indicate that neuromodulation therapy, using SCS, can mitigate the imbalances in cardiac reflex
control arising from acute cardiac stress and thereby has the potential to slow the progression of
chronic heart disease.
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CHAPTER 1
INTRODUCTION

The Cardiac Nervous System
The cardiac nervous system is a subdivision of the autonomic nervous system, which
includes the sympathetic and parasympathetic efferent branches. It functions to reflexly control
physiological functions like heart rate, cardiac contractility, and more. The cardiac nervous system
consists of afferent, efferent, and multiple processing neuronal networks, including those located
within the central nervous system (CNS) and within peripheral ganglia (Armour 1999; 2004). The
afferent neurons transduce cardiac sensory information to the cardiac nervous system using
intracardiac (intrinsic cardiac nervous system) and extracardiac (stellate, middle cervical, nodose, and
dorsal root) ganglia (Armour 1986a; 1986b; Bosnjak and Kampine 1989; Brown 1967; Hopkins and
Armour 1989; Horackova and others 1996; Kuo and others 1984). Afferent input provided to the
cardiac nervous system includes that from arterial baroreceptors, chemoreceptors (cardiac and
peripheral), and multimodal cardiopulmonary and somatic afferents (Armour 1999; 2004). For
cardiac control, the parasympathetic preganglionic neurons originate in the nucleus ambiguus and
the dorsal motor nucleus in the medulla oblongata and travel through the cranial nerve to synapse
on postganglionic parasympathetic neurons contained within the intrinsic cardiac ganglia (Cheng and
others 1999; Hopkins and Armour 1984; Plecha and others 1988). For cardiac control, the
sympathetic preganglionic neurons originate from the intermediolateral cell column of the spinal
cord, exiting at the T1-T5 levels, to synapse with postganglionic neurons in the intrathoracicextracardiac ganglia and the intrinsic cardiac ganglionated plexuses (Forsgren and others 1990;
Hopkins and Armour 1984; Horackova and others 1999; Moravec and Moravec 1987).
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The intrinsic cardiac and other intrathoracic autonomic ganglia contain local circuit neurons
(LCN). The primary function of this neural population is to interconnect afferent and efferent
neural components within and between intrathoracic autonomic ganglia (Armour 1999; 2004; 2008).
Peripheral neural interconnections are thought to contribute to organ level processing and
functional control (Armour 1986a; Armour 1991; Armour and Janes 1988; Armour and others 1997;
Darvesh and others 1987; Yuan and others 1994). Cardiac function is regulated by the interactions
between central and peripheral neuronal components of the cardiac nervous system (Armour 2004).
These interactions are manifest as interdependent feedback loops between intracardiac and
extracardiac ganglia, spinal cord, brainstem, and higher centers of the central nervous system
(Armour 2004). The intrinsic cardiac nervous system is thought to control short-term function, with
longer-term function being controlled by progressively higher neural networks (Armour 1999; 2004;
2008). These interdependent networks interact ultimately to control the autonomic efferent
outflows via the sympathetic and parasympathetic nervous systems (Armour 2004).
Parasympathetic activation decreases cardiac chronotropism (rate), dromotropism
(conduction), and inotropism (contractility), while sympathetic activation exerts opposite effects
(Burwash and others 1993; Randall and others 1996). Normal cardiac function is also regulated
through the influence of circulating hormones, such as angiotensin II, and circulating
catecholamines acting on both neural components and the cardiac end-effectors (Ardell 2004).
Figure 1 summarizes many of the salient neurohumoral interactions that ultimately result in control
of cardiac function in the normal and stressed heart.
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Figure 1.1. A schematic of the neurohumoral components and their interactions that contribute to
the control of heart function. DRG – dorsal root ganglia. LCN – local circuit neurons. Aff. –
afferent. C1-C2 – Cervical spinal segments 1-2. T1-T4 – Thoracic spinal segments 1-4. Ang I –
Angiotensin I. Ang II – Angiotension II. β1 – Beta 1-adrenergic receptors. M2 – Muscarinic
receptors subtype 2. ATP – Adenosine triphosphate. cAMP – Cyclic adenosine monophosphate. Gs
– Gs-protein subunit. Gi – Gi-protein subunit. AC – Adenylate cyclase. (adapted from Ardell and
Foreman 2009)
Ischemic Cardiac Disease and Its Effect on the Cardiac Nervous System
Approximately every minute an American dies from a coronary event making coronary heart
disease a significant health concern for a large portion of the U.S. population (Lloyd-Jones and
others 2009). The incidence of coronary heart disease, including acute coronary syndrome, is
estimated at 935,000 new and recurrent attacks in the U.S. per year (Lloyd-Jones and others 2009).
Restricting the supply of blood and oxygen to the heart leads to myocardial ischemia (Thygesen and
17

others 2007). Acute coronary syndrome consists of MI and angina pectoris (Thygesen and others
2007). If severe enough, MI induces changes in the cardiac environment including increasing the
propensity for arrhythmia formation, cardiac cell death, and the potential for progression into heart
failure (Thygesen and others 2007).
Disease states alter multiple components of the cardiac nervous system (Armour 1999).
Cardiac afferent neurons are thought to be the first component affected. For example, regional
ventricular ischemia increases cardiac sensory activity via activating multimodal cardiac sensory
neurites (Armour 1999; Huang and others 1996). MI reflexly activates intrinsic cardiac neurons
leading to adverse function such as arrhythmia formation and compromised mechanical activity
(Foreman and others 2000). MI likewise causes the reflex activation of efferent neurons in the
stellate and middle cervical ganglia, contributing to the increase in postganglionic sympathetic
activity (Ardell and others 2009). Central processing of afferent inputs at the level of the spinal cord
and brainstem contribute to reflex evoked changes in efferent outflows (Armour 1999; 2004).
Research into the effects of MI on the heart and the cardiac nervous system has identified two
distinct sets of effects, short-term and long-term (Armour 1999; 2004). In the short term, excessive
reflex activation of parasympathetic and sympathetic efferent neurons can elicit atrial or ventricular
arrhythmias (Armour 1976; Armour and others 2005; Cardinal 2004; Carlson and others 1992;
Huang and others 1994; Schwartz and others 1978). Excessive catecholamine release, in reflex
response to ischemia, is also cardio-toxic (Armour 1999). Over longer periods of time, cardiac
disease induces neural remodeling of the cardiac nervous system (and heart tissues) and this
contributes to the progression of cardiac pathologies (Armour 1999; 2004). Examples of neural
remodeling include focal denervation of nerve projections through the infarct zone and
hyperinnervation in the border zone surrounding the region of ischemic insult (Chen and others
2001). Changes in innervation density can be accompanied by focal changes in receptor density,
18

receptor coupling and neurotransmitter release (Chen and others 2007; Chen and others 2001; Zipes
2008). Heterogeneity in efferent inputs to the heart are a major contributor to adverse
consequences of cardiac disease (Armour 2004).
Cardiac Arrhythmias and the Cardiac Nervous System
Heterogeneous efferent input to the heart is a major risk factor for cardiac arrhythmias
(Armour 2004; Zipes 2008). In normal hearts, the sympathetic and parasympathetic nervous
systems form a interdependent neural substrate to regulate regional cardiac electrical activity
(Armour 2004). MI-induced alterations in cardiac tissues by themselves directly increase the
arrhythmogenic substrate of the heart (Armour 2004). For example, myocardial infarct disrupts
electrical pathways within the heart, leading to arrhythmia formation through reentrant circuits
(Iwasaki and others 2011). These reentrant circuits are self-perpetuating waves of cardiac electrical
activity that result in the formation of cardiac arrhythmias, including tachycardia and fibrillation
(Armour 1999; Iwasaki and others 2011). Superimposed on the alterations of electrical substrate,
imbalances of neuronal control can facilitate arrhythmia formation (Armour 1999). Recent evidence
suggests that nerve sprouting in and near the infarct site can contribute to this imbalance of neural
control (Chen and others 2001). MI-induced nerve sprouting is found predominantly in sympathetic
nerves (Chen and others 2001), likely contributing to imbalanced neurotransmitter release during MI
stress (Zipes 2008). Heterogeneous adrenergic neural activity evokes imbalances in myocyte
excitability and refractoriness, both contributing to cardiac electrical instability (Zipes 2008). These
data point to the interdependence of neural and local myocyte factors in the electrical stability of
normal and ischemic stressed hearts (Zipes 2008). Therapies that reduce the heterogeneity, either by
targeting the myocyte substrate or the neural mechanisms that modulate it, should translate into
decreased risk of cardiac arrhythmias (Zipes 2008).
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Recent studies have used an experimental model of electrically-induced atrial fibrillation (AF)
to study cardiac arrhythmia formation and mechanisms to control them (Armour and others 2005;
Cardinal and others 2006; Richer and others 2008). One model involves stimulating mediastinal
nerves that course over the ventral and ventrolateral surfaces of the superior vena cava (Armour and
others 2005). Stimulation of these nerves creates self-terminating periods of AF (Armour and
others 2005). While this model differs in some respect from cardiac disease-created AF, it allows for
the study of how neuronal imbalances within the cardiac nervous system can influence the
formation of arrhythmias and potentially how aspects of that neural population can be targeted to
modulate the potential for AF (Armour and others 2005; Cardinal and others 2006; Richer and
others 2008).
Neuromodulation as a Novel Approach to Treat Heart Disease
Cardiac disease is a multi-factored process that involves cardiac tissues and the
neurohumoral factors that modulate the heart (Armour 1999; 2004). Cardiac dysfunction, as occurs
in acute coronary syndrome, can be targeted by therapies directed at cardiomyocytes, the
neurohumoral components that regulate them or by physical means as with restoration of blood
flow (Armour 1999; 2004). Coronary artery bypass graft and balloon angioplasty are the primary
mechanical therapies that restore blood flow and are effective in a majority of patients (Andrade and
others 2011; Mannheimer and others 1998). However, a subset of patients are not candidates for
such an approach or conversely, exhibit refractory angina even after revascularization (Mannheimer
and others 1998).
Neuromodulation-based therapies for cardiac disease focus on targeting neuronal
components within the cardiac nervous system to achieve effects. One such neuromodulatory
approach involves cryo- or electrical ablation of specific neuronal targets of the intrinsic cardiac
nervous system as an adjunct therapy to traditional ablation of cardiomyocytes to control atrial
20

arrhythmias (Burkhardt and Natale 2009). This therapy is predicated on the hypothesis that
disruption of select parts of the cardiac nervous system can stabilize the heart and reduce the
arrhythmogenic potential of the heart (Armour 2008). The resulting lesions eliminate
subcomponents of the neural networks that influence cardiac function, but the potential for sudden
cardiac death (SCD) still remains (Armour 2008). Importantly, while ablation therapy has shown
some positive short-term effects, the interconnectivity and processing ability of remaining parts of
the cardiac nervous system along with their remodeling post-ablation allows for those remaining
components of the cardiac nervous system to still promote the formation of arrhythmias in the long
term (Armour 2008).
Neuromodulation therapy can use pharmacological blockade of receptors to impact
neuronal activity (Armour 1999; Association 2007; Marieb 2004). These pharmacological
approaches can consist of agents like non-selective β-adrenergic antagonists or specific agents like αor β1-selective adrenergic receptor blockers (Association 2007). While pharmacological therapies
can be effective in combating cardiac dysfunction including progression into congestive heart failure
and potential for SCD (Association 2007), the cardiac nervous system isn’t the only target of these
pharmacologically based therapies (Marieb 2004). The neuropharmacologically-based therapies
often result in numerous unwanted side effects, such as diarrhea, rash, slow heart rate, and
impotence, reducing the indications for use and are also subject to patient non-compliance
(Association 2007).
An emerging neuromodulation therapy involves electrical stimulation of various aspects of
the cardiac nervous system to treat cardiac pathophysiology. For example, vagal nerve stimulation is
currently being evaluated to treat heart failure (Schwartz and De Ferrari 2009). This approach is
predicated on the hypothesis that increasing parasympathetic tone will counteract the increase in
sympathetic activity seen in heart failure and thereby slow progression of congestive heart failure
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(Schwartz and De Ferrari 2009). In one study of animals with healed infarcts, vagal stimulation
reduced heart rate by 75 beats per minute during exercise and reduced the propensity for ventricular
fibrillation from 92% in control to 12% during the exercise stress (Vanoli and others 1991). Recent
studies also have shown that low-level vagal nerve stimulation reduces the arrhythmogenic potential
of the atria in response to rapid atrial pacing while also reducing sympathetic nerve activity (Sha and
others 2011; Shen and others 2011b). These studies indicate that induced alterations in autonomic
efferent outflows can be moderated by electrical neuromodulation to affect cardiac electrical stability
(Zipes 2008).
Another approach for neuromodulation involves direct electrical stimulation of the carotid
baroreceptors. This therapy is predicated on the hypothesis that increased baroreceptor activity will
reflexly increase parasympathetic activity and decrease sympathetic activation to the heart (Sabbah
and others 2011; Wang and others 1991; Zucker and others 2007). This therapy elicited a reduction
in the progression of congestive heart failure in response to the cardiac stress of rapid ventricular
pacing (Zucker and others 2007). It remains to be determined if such an integrated baroreflex type
approach is effective against other models of cardiac disease (e.g. MI, mitral regurgitation, etc.).
A third major approach using electrical neuromodulation involves spinal cord stimulation
(SCS). In the treatment of heart disease, SCS is traditionally performed at the T1-T3 levels with
electrical stimuli applied to the dorsal aspects of the spinal cord. This level includes the spinal
segments where the sympathetic efferent nerve fibers exit and the cardiac sympathetic afferent nerve
fibers enter the spinal cord from the heart (Armour 1999; 2004). Clinical research has demonstrated
that high thoracic SCS significantly reduces the presentation of anginal symptoms, the onset of
angina and increases exercise tolerance (Mannheimer and others 1993; Mannheimer and others
1998; Sanderson and others 1992; Sanderson and others 1994). In addition, SCS decreased the STsegment depression, a marker of MI, and increased the time before ST-segment depression onset
22

during a progressive exercise stress test (Eliasson and others 1993; Mannheimer and others 1993;
Sanderson and others 1992; Sanderson and others 1994). Clinical investigators have suggested that
the cardiac benefits of SCS result from improved oxygen supply/demand balance in the stressed
heart (Mobilia and others 1998), but little hard evidence has been put forth to support this concept
(Kingma and others 2001).
Basic science research has confirmed and extended the potential cardioprotective effects
evoked by SCS (Ardell and others 2009; Armour and others 2002; Armour and others 2005;
Cardinal and others 2006; Foreman and others 2000; Qin and others 2008; Richer and others 2008;
Southerland and others 2007). High thoracic SCS has been shown to decrease MI-induced
sympathetic activation in reflex response to ischemic stress and to reduce the arrhythmogenic
potential resulting from ischemic stress (Ardell and others 2009; Cardinal and others 2006;
Southerland and others 2007). Other studies have demonstrated that SCS modulates activity in the
middle cervical and intrinsic cardiac ganglia and within the spinal cord, attenuating their reflex
response to ischemic stress (Ardell and others 2009; Ding and others 2008a; Ding and others 2008b;
Foreman and others 2000; Qin and others 2008; Southerland and others 2007). Pre-emptive SCS
likewise activates protein kinase C in ventricular myocytes, contributing to the cardioprotective
effects against the stress of acute MI (Southerland and others 2007). High thoracic SCS-induced
cardioprotection to ischemic stress occurs without significant changes in cardiac blood flow and
without significant changes in basic hemodynamic function (Kingma and others 2001). Transection
of the ansae subclavian, eliminating afferent and efferent interconnections between the spinal cord
and peripheral aspects of the cardiac nervous system, prevents SCS-induced changes in middle
cervical and intrinsic cardiac neuronal activity (Cardinal and others 2006; Foreman and others 2000).
These data demonstrate that thoracic SCS exerts many of its beneficial effects on cardiac function
by; 1) targeting the cardiac nervous system and 2) directly impacting cardiac tissue (Ardell and others
23

2009; Armour 2008; Armour and others 2002; Armour and others 2005; Cardinal and others 2006;
Foreman and others 2000; Southerland and others 2007).
The targeting of neural elements that regulate cardiac function was initially evaluated at the
high thoracic spinal cord level, where the sympathetic efferent and afferent neurons enter and exit
the cord (Ding and others 2008a; Ding and others 2008b; Qin and others 2008). This high thoracic
location mitigates numerous deleterious effects induced by cardiac ischemic pathologies (Ardell and
others 2009; Armour and others 2002; Cardinal and others 2006; Foreman and others 2000;
Southerland and others 2007). Recent anatomical and functional studies have indicated that there
may be other potential sites within the neural hierarchy for cardiac control where SCS may exert
cardioprotective effects in response to cardiac stress (Ding and others 2008b; Qin and others 2008).
The high cervical region of the spinal cord is one such site. The high cervical spinal segments
receive parasympathetic and sympathetic afferent nociceptive inputs (Chandler and others 1996;
Chandler and others 2000; Foreman 1999). It is also reciprocally interconnected with lower levels of
the spinal cord and with supraspinal elements of the cardiac nervous system (Marieb 2004).
Previous work has indicated that high cervical SCS attenuates afferent transduction of cardiac
ischemia (Ding and others 2008b; Gonzalez-Darder and others 1991; Qin and others 2008). The
high cervical spinal segments also modulate spinal cord reflex processing of autonomic outflow for
thoracic and visceral tissues (Ding and others 2008a; Ding and others 2008b; Qin and others 2007a;
Qin and others 2008; Qin and others 2007b). These findings indicate that high cervical spinal
segments may therefore provide a site higher in the cardiac neural hierarchy for SCS to act upon
(Ding and others 2008b; Qin and others 2008).
To investigate the specific neuronal targets of neuromodulation, this dissertation is
predicated on the following hypotheses: 1) The cardiac nervous system contains a complex hierarchy
of reflex control systems that contribute to control of regional cardiac function; 2) The cardiac
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nervous system is disrupted by cardiac stressors contributing to deleterious effects on that neural
control system and the myocardium it modulates; and 3) Stabilization of select aspects of the cardiac
nervous system through neuromodulation can mitigate the deleterious effects of cardiac stressors on
the neural components of the cardiac nervous system and the myocardium thereby inducing states
of cardioprotection. To test these hypotheses, this dissertation was divided into three specific aims
which are as follows.
Specific Aims
Specific Aim 1: To determine whether high cervical cord neurons can modify infarct size
and potential for SCD in response to ischemic stress.
Myocardial ischemia is known to impact cardiomyocytes directly and the cardiac nervous
system that controls them (Armour 2008). High thoracic SCS has recently been shown to have antiischemic properties that improve the ability of the heart to function following MI (Cardinal and
others 2004; Eliasson and others 1993; Mannheimer and others 1993). Pre-emptive thoracic SCS
reduces infarct size as well as activates cardiomyocyte protein kinase C pathways (Southerland and
others 2007). It also stabilizes the electrical properties of the ventricle in response to transient MI
(Cardinal and others 2004; Southerland and others 2007). Neurons in the upper cervical spinal cord
are known to modify sensory transduction from the periphery, including those arising from the
thorax and viscera (Chandler and others 1993; Ding and others 2008b; Foreman and others 2004).
Pre-emptive SCS from the high cervical region modulates dorsal horn sensory afferent signaling
from the ischemic myocardium (Ding and others 2008a). This effect may reflect activity of cervical
propriospinal pathways that release dynorphin at the thoracic spinal cord to modulate nociceptive
signaling (Ding and others 2008b). The C1-C2 region is interconnected with lower levels of the
cord and with cardiovascular regions of the brainstem, including the nucleus tractus solitarii
(Chandler and others 1993; Ding and others 2008b; Foreman and others 2004). These data indicate
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the potential of the upper cervical spinal segments to act as a processing center within the cardiac
neuronal hierarchy for cardiac control and a site for potentially modifying the deleterious cardiac
effects of MI (Ding and others 2008a; Qin and others 2008). Chapter 2 will focus on the hypothesis
that high cervical SCS neuromodulation imparts cardioprotective effects in response to MI by
modulating sympathetic and parasympathetic outflows to the heart. Cardioprotective effects
evaluated will include infarct size and the potential for MI-induced SCD. This aim will determine if
those cardioprotective effects involve 1) descending projections from the cervical to the thoracic
spinal cord and 2) the differential roles of high cervical SCS-mediated changes in sympathetic versus
parasympathetic efferent outflows and their response to acute MI.
Specific Aim 2: To determine if SCS modulates primary afferent neural transduction of MI.
SCS has been shown to modulate the MI-induced increase in activity of neurons in
intrathoracic ganglia (Ardell and others 2009). These ganglia, including intrinsic and extracardiac
ones, contain cardiac efferent and afferent and local circuit neurons (Ardell and others 2009;
Foreman and others 2000). SCS does not interrupt primary efferent projections to the heart
(Armour and others 2002). Within peripheral ganglia of the cardiac nervous system, data indicate
that SCS may target the local circuit neurons to blunt reflex activation of autonomic efferent outflow
(Ardell and others 2009; Armour 2008; Foreman and others 2000; Qin and others 2008). Primary
cardiac afferent neurons and their response to MI in association with SCS neuromodulation have yet
to be studied.
Previous studies identifying SCS effects on cutaneous blood flow have suggested that SCS
can impose an “efferent” function on afferent neurons (White and Helme 1985). Whether such
antidromic evoked responses are manifested in cardiac afferents in response to SCS have yet to be
determined. Chapter 3 will examine the hypothesis that high thoracic SCS modifies the ability of
primary cardiac afferent neurons to respond to the stress of MI, either by direct antidromic
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activation of primary cardiac afferent neurons or through altering the cardiac sensory milieu. To
investigate this hypothesis, the activity of primary cardiac afferent neurons (nodose and DRG) will
be examined in response to transient MI, with and without pre-emptive SCS neuromodulation.
Specific Aim 3: To determine if SCS targets intrinsic cardiac neurons to attenuate
neuronally-mediated atrial arrhythmias.
Excessive activation of discrete inputs to the intrinsic cardiac nervous system have been
demonstrated to create atrial arrhythmias in normal and diseased states (Armour and others 2005;
Choi and others 2011; Richer and others 2008; Shen and others 2011a). As described previously, the
stimulation of select intrathoracic mediastinal nerves evokes reproducible and self-terminating
periods of AF (Armour and others 2005). This model of AF is known to involve both
parasympathetic and sympathetic efferent mechanisms (Armour and others 2005; Richer and others
2008). SCS has previously been shown to decrease the induction of AF following mediastinal nerve
stimulation (MSNS), but the neural mechanisms underlying this response have not been determined
(Cardinal and others 2006). Therefore, Chapter 4 will investigate the hypotheses that: 1) MSNS
activates select neuronal subpopulations within the intrinsic cardiac nervous system (ICN) in
association with the induction of AF; 2) stabilization of those populations within the intrinsic cardiac
nervous system via neuromodulation (electrical or pharmacological) blunts the capacity of the ICN
to respond to excessive inputs; and 3) stabilization of intrinsic cardiac neurons suppresses the atrial
arrhythmogenic potential. The neurochemical phenotype and activity of right atrial ganglionated
plexus neurons along with AF induction characteristics in response to MSNS and neuromodulation,
electrical or pharmacological, will be examined to test this hypothesis.
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Abstract
To evaluate whether cervical spinal neurons can influence cardiac indices and myocyte
viability in the acutely ischemic heart, the hearts of anesthetized rabbits subjected to 30 min of left
anterior descending (LAD) coronary arterial occlusion (CAO) were studied 3 hours after
reperfusion. Control animals were compared to those exposed to pre-emptive high cervical cord
stimulation (SCS; the dorsal aspect of the C1-C2 spinal cord was stimulated electrically at 50 Hz; 0.2
ms; 90% of motor threshold, starting 15 min. prior to and continuing throughout CAO). Four
groups of animals were so tested: 1) neuroaxis intact; 2) prior cervical vagotomy; 3) prior transection
of the dorsal spinal columns at C6; and 4) following pharmacological treatment [muscarinic
(atropine) or adrenergic (atenolol, prazosin or yohimbine) receptor blockade]. Infarct size (IS) was
measured by tetrazolium expressed as percentage of risk zone. C1-C2 SCS reduced acute ischemia
induced IS by 43%, without changing the incidence of sudden cardiac death (SCD). While SCSinduced reduction in IS was unaffected by vagotomy, it was no longer evident following transection
of C6 dorsal columns or atropinization. Beta-adrenoceptor blockade eliminated ischemia-induced
SCD, while alpha-receptor blockade doubled its incidence. During SCS, myocardial ischemia
induced SCD was eliminated following vagotomy while remaining unaffected by atropinization.
These data indicate that, in contrast to thoracic spinal neurons, 1) cranial cervical spinal neurons
affect both adrenergic and cholinergic motor outflows to the heart such that 2) their activation
modifies ventricular infarct size and lethal arrhythmogenesis.
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Introduction
Myocardial ischemia represents a complex cardiovascular stress that involves cardiomyocytes
as well as neurohumoral control of cardiomyocytes (Kajstura et al., 2006; Armour, 2008).
Imbalances in such neurohumoral control, especially those leading to excessive sympathetic efferent
neuronal activation, have been associated with an enhanced arrhythmogenic substrate (Schwartz,
2001) as well as deterioration of pump function (Armour, 2008; Dell'Italia & Ardell, 2004).
Conversely, endogenous or exogenous mechanisms that maintain parasympathetic efferent neuronal
control during transient myocardial ischemia have been proposed to exert cardioprotective effects thereby reducing any risk of sudden cardiac death (Vanoli et al., 2008).
Neuromodulation-based therapies that underlie the emerging field of neurocardiology are
known to affect the progression of cardiac pathologies. For instance, pharmacological therapies that
employ β-adrenoceptor blockade and/or angiotensin-converting enzyme inhibition (Hankes et al.,
2006; Perry et al., 2002) modulate not only cardiomyocyte function directly, but also indirectly by
mitigating adverse remodeling of the cardiac neuronal hierarchy (Armour, 2008; Hankes et al., 2006;
Tallaj et al., 2003).
Spinal cord stimulation (SCS) has been reported to exhibit anti-ischemic properties that
include increased exercise tolerance (Hautvast et al., 1998), diminished ST segment deviation during
stress (Cardinal et al., 2004; Hautvast et al., 1998; Odenstedt et al., 2011), and improved lactate
metabolism (Mannheimer et al., 2002). Yet, anginal pain can still be evoked in the presence of SCS
when the stress (e.g. exercise) is of sufficient magnitude to induce critical levels of myocardial
ischemia (Eddicks et al., 2007; Mannheimer et al., 2002).
Evidence indicates that neurons in the thoracic spinal cord play a role in processing afferent
inputs arising from the stressed heart (Ding et al., 2008a; Ding et al., 2008b). In fact, electrical stimuli
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delivered to neurons within the thoracic spinal cord have been shown to reduce electrical instability
of the stressed ventricle (Cardinal et al., 2004; Cardinal et al., 2006; Odenstedt et al., 2011). We have
proposed that the cardioprotection elicited by delivering pre-emptive electrical stimuli to the
thoracic spinal cord acts to stabilize excessively active intrinsic cardiac local circuit neurons involved
in transducing the ischemic event (Armour, 1997; Armour et al., 2002). Such therapy also activates
cardiomyocyte protein kinase C (PKC) pathways and reduces infarct size in response to transient
periods of myocardial ischemia (Southerland et al., 2007).
Neurons in the C1-C2 spinal cord are known to be involved in modifying pain transmission
arising from intrathoracic and abdominal viscera (González-Darder et al., 1991) presumably because
to the fact that they receive afferent neuronal inputs from sympathetic ascending projections and
nodose ganglion neurons (Chandler et al., 1993; Ding et al., 2008a). In addition, the C1-C2 spinal
cord region is known to be interconnected reciprocally with cardiovascular-related medullary
neurons (Foreman et al., 2004). As it remains to be established whether neurons in the cervical spine
are involved in cardiac neuromodulation and, if so, in what manner, this study was devised to
determine whether neuromodulation of cervical spinal neurons can affect cardiac indices,
particularly in the presence of myocardial ischemia.
If cervical SCS does indeed impart cardioprotection, as manifested by changes in infarct size
and the potential for sudden cardiac death, we also sought to elucidate whether such
cardioprotection involves not only 1) cervical spinal descending projections to the thoracic cord, 2)
but also whether supraspinal projections arising from the C1-C2 region modify parasympathetic
outflow to impact cardiac function in response to ischemic stress – something not evident from
thoracic SCS. Thus we sought to determine whether such a therapeutic intervention might involve
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adrenergic versus cholinergic efferent neurons from high cervical spinal cord neuronal inputs and
whether such modulation imparts potential therapeutic benefits to the ischemic ventricle.

Materials and Methods
Subjects. One hundred eighty two New Zealand White rabbits of either sex, weighing between
1.7 and 3.8 kg (2.7±0.4 kg), were used in these studies. Seventeen of these were excluded from final
analysis for technical reasons. Because the rabbit heart has minimal collateral blood flow, this
animal model produces a distinct, homogenous ventricular risk zone, which is ideal to directly
evaluate therapeutic interventions for transient myocardial ischemia (Maxwell et al., 1987). All
experiments were performed in accordance with the guidelines for animal experimentation described
in the “Guiding Principles for Research Involving Animals and Human Beings”
(Am.Physiol.Society, 2002). The Institutional Animal Care and Use Committee of East Tennessee
State University approved these experiments.
Surgical preparation. Rabbits were anesthetized with intravenous pentobarbital sodium (30
mg/kg iv via ear access, supplemented as needed with 2 mg/kg iv if the animal responded to
noxious stimuli or an increase in arterial blood pressure was observed). The trachea was intubated
via a cervical incision and mechanical ventilation initiated and maintained with a positive pressure
ventilator (MD Industries, Mobile, AL) using 100% O2. Core body temperature was maintained at
38˚C via a circulating water heating pad. The right carotid artery was cannulated for monitoring
blood pressure and the right jugular vein cannulated to administer anesthetic agents and drugs. Heart
rate was assessed from a Lead II electrocardiogram. All hemodynamic data were recorded
concurrently on a Gould model TA6000 recorder. For protocols 1d and 3b (fig. 1), both cervical
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vagi were exposed by a midline cervical skin incision and isolated in order that bilateral vagotomy
could be performed.
Animals were placed in ventral recumbency and a laminectomy was performed at the C2
level followed by the subdural placement of two plate electrodes (2 x 3 mm) slightly to the left of the
midline at the C1-C2 level. Spinal cord stimulation (SCS) was performed via these indwelling
electrodes which were connected to a Grass S88 stimulator (Grass Instruments, Quincy, MA) using
a constant current stimulus isolation unit (Grass PSIU 6G). The parameters used to stimulate the
spinal cord were 50 Hz, 0.2 ms duration and at an intensity of 90% of motor threshold. SCS
stimulation parameters were chosen because of their proven therapeutic benefits (Mannheimer et al.,
2002) including its documented ability to reduce infarct size in response to transient myocardial
ischemia (Southerland et al., 2007). To determine the adequate stimulus intensity, the current
intensity was progressively increased until minor muscle contractions were observed in the cervical
neck region and/or left upper shoulder (motor threshold). Current intensity was set at 90% of
motor threshold for the experimental protocols; this intensity averaged 0.27 + .07 (SD) mA. The
rostral and caudal poles were chosen as cathode and anode, respectively, according to current clinical
practice (Mannheimer et al., 2002). Motor threshold determinations were repeated at the end of the
experimental protocols to determine the stability of the stimuli intensity. For protocols 1c and 3a
(Fig. 1), an additional laminectomy was performed at the C6 level, and a midline incision was made
in the spinal cord and extended approximately 2-3 mm laterally on each side to transect the dorsal
columns of the spinal cord at that level.
Animals were rotated to their right-side and a thoracotomy was performed in the left fourth
intercostal space. The pericardium was opened to expose the heart. A 2-0 silk suture on a curved,
tapered needle was passed around the left anterior descending coronary artery one-third of the
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distance from the left ventricular base to apex. Regional cyanosis and bulging were observed when
the ends of the suture were pulled through a small polyethylene tube to form a snare, which was
then secured by clamping the tube with a hemostat. Cyanosis and regional diskinesia were observed
in the region downstream to the occluded vessel and both disappeared immediately upon
reperfusion. The risk zone consisted of the myocardial tissue perfused by the snared coronary artery;
the non-risk zone consisted of the remainder of the left ventricle. A 20-minute stabilization period
preceded the onset of each experimental protocol.
Experimental protocols. Figure 1 summarizes the experimental protocols used for each of the 11
groups of rabbits studied. Each group underwent a dorsal laminectomy at the C2 level prior to being
subjected to 30 min. of coronary arterial occlusion (CAO) followed by a 3-hr reperfusion period.
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Figure 1. Protocols for the in situ rabbit heart experiments. The ventricles in each respective
group were exposed to regional ischemia (open boxes) with or without pre-emptive C1-C2 spinal
cord stimulation (SCS: filled boxes). The control group (Protocol 1) consisted of 30 min. of left
coronary artery occlusion (CAO) followed by a 3-hr reperfusion period. A similar 30 min. CAO and
3 hr reperfusion stress was utilized to evaluate all neuromodulation treatments (protocols 2 and 3).
For pre-emptive SCS, SCS was delivered at frequencies of 50 Hz, 200μs and 90% motor threshold.
For protocols 1 and 2, the arrow indicates the time when pretreatment with the vehicle (control),
adrenoceptor blocking agents (prazosin, yohimbine or atenolol) or the muscarinic blocking agent
atropine occurred. For protocols 1 and 3, X indicates the time of dorsal column transection at the
C6 spinal segment (C6 DCNx) or bilateral transection of the cervical vagosympathetic trunk
(vagotomy). Specific subsets for protocols 1 (a to d) and 3 (a and b) are indicated on the left.
Protocol 2 has 5 subsets, as determined by indicated vehicle or drug injection.

Animals in protocol 1 (n = 40) were subjected to 30 min. of regional ventricular ischemia
followed by a 3-hr reperfusion period. Nine of these animals were in the control coronary occlusion
group (protocol 1a: sham SCS), 9 animals were pretreated with atropine (0.2mg/kg, iv) 30 min. prior
to the onset of regional ischemia (protocol 1b). This dose of atropine was sufficient to block the
bradycardic responses to vagal stimulation. Eleven animals underwent bilateral transection of the
dorsal columns at the C6 spinal level 1 hour prior to the onset of regional ischemia (protocol 1c).
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Selective transection of C6 dorsal columns was confirmed post-mortem. Eleven animals had their
cervical vagi transected 1 hour prior to the onset of regional ischemia (protocol 1d).
Pre-emptive electrical neuromodulation. Animals in this part of the study (protocols 2-3) were
subdivided into seven separate groups. Each group was subjected to 46 min. of SCS initiated 15 min.
prior to the onset of the 30 min. coronary artery occlusion and terminated 1 min. after release of the
coronary artery occlusion. The ischemic period was followed by a 3-hr reperfusion period. The
duration and time point for the onset of pre-emptive SCS applied to upper cervical segments of the
spinal cord were based upon its effectiveness to reduce infarct size when delivered to the high
thoracic cord (Southerland et al., 2007).
Animals in protocol 2 (n = 94) were subjected to 46 min. of C1-C2 SCS, as described above.
Fifty-four of these animals underwent C1-C2 SCS with vehicle control, run in a blinded fashion with
each of the protocols using selective autonomic receptor blockade. To determine whether
adrenergic or muscarinic receptor blockade affected pre-emptive C1-C2 SCS-induced
cardioprotection, 40 additional animals were subjected to protocol 2 15 min. after either the α1adrenoceptor blocking agent prazosin (0.15mg/kg iv; n = 11), the α2-adrenoceptor blocking agent
yohimbine (1mg/kg iv, n = 12), the β1-adrenoceptor blocking agent atenolol (2mg/kg iv; n = 8), or
the muscarinic receptor blocking agent atropine (0.2mg/kg, iv; n = 9) was administered. The
prazosin dose was selected because of its effectiveness in blocking the hypertensive response to
intravenous injections of phenylephrine (100 μm/1 ml). The dose of atenolol blocked the
tachycardiac response to intravenous isoproterenol (100 μm/1 ml). The dose of yohimbine was
selected according to its effectiveness in stabilizing neuronal processing within the intrinsic cardiac
nervous system (Richer et al., 2008). The dose of atropine was sufficient to block any bradycardia
responses elicited by vagal stimulation.
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Protocol 3 (n=31) evaluated the potential contributions of intersegmental propriospinal and
supra-spinal/parasympathetic interconnections in mediating the cardioprotection to C1-C2 SCS. To
determine whether C1-C2 SCS effects on myocyte cell death and electrical stability involved
intersegmental spinal cord connections, we subjected 15 animals to bilateral transection of the dorsal
columns at C6 (protocol 3a) 1 hr prior to the pre-emptive SCS-coronary artery occlusion stress.
Selective transection of C6 dorsal columns was confirmed post-mortem. To determine whether C1C2 SCS mediated effects on cardiac viability and electrical stability involved supraspinal pathways,
reflected back to the heart via the parasympathetic efferent pathways, 16 animals in protocol 3b were
subjected to bilateral cervical vagotomy 1 hr prior to the SCS-coronary artery occlusion stress.
Infarct measurement. At the end of each experiment, the hearts were rapidly excised, mounted
on a modified Langendorff apparatus, and perfused with 0.9% saline at 37˚C to remove blood from
the coronary circulation. Following re-occlusion of the coronary artery that had been occluded
previously, 2- to 9-μm fluorescent polymer microspheres (Duke Scientific, Palo Alto, CA) were
injected into the aortic perfusion fluid to demarcate the ventricular region at risk. After removing
both atria, the rest of the heart was weighed and then frozen at -20˚C. The heart was then cut into 2mm-thick slices parallel to the atrioventricular groove. Tissue slices were incubated for 20 min. at
37˚C in 1% triphenyltetrazolium chloride (TTC) and sodium phosphate buffer (pH 7.4). Tissue
slices were then placed in 10% formalin to improve the contrast between stained and unstained
tissue. Areas of infarction (TTC negative), risk zone (negative fluorescence under UV light), and
non-risk zone (positive fluorescence under UV light) were traced onto plastic overlays. These areas
were measured using computer-assisted planimetry (Image Research). Infarct and risk zones were
calculated by multiplying each area by tissue thickness and their products summed. Infarct size is
expressed as a percentage of risk zone.
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Immunohistochemistry. A total of 24 animals were used for this section of the study. Following
the 3 hr reperfusion, animals were given a large dose of pentobarbital and then perfused
transcardially with 2 L of normal saline followed by 2 L of 4% paraformaldehyde in phosphate
buffered saline (PBS), pH 7.4. The T2 spinal cord (identified by placing a small dot of Pontamine
blue dye on the dorsal surface of the C8 spinal cord prior to its removal) was excised and postfixed
as described previously (Hua et al., 2004). Consecutive 50 µm sections were cut with a cryostat
(Leica Microsystems Inc., Bannockburn, IL) at -20oC and placed immediately into wells of
polypropylene plates containing PBS. Sections were processed for the presence of c-Fos
immunoreactivity as described previously (Hua et al., 2004). Briefly, tissues were rinsed in PBS for
15 min. and then permeabilized in PBS containing normal donkey serum (NDS; Millipore, Billerica,
MA) and Triton-X-100 (Sigma) for 20 min. The sections were then treated with H2O2 (Fisher,
Pittsburgh, PA) to quench endogenous peroxidase activity. The sections were rinsed with PBS and
permeabilized again. The sections were then incubated in a 10% NDS blocking solution. Following
blocking, the sections were incubated in c-Fos antibody from goat (1:15000 in PBS; Cat. # sc-52-G,
Santa Cruz Biotechnology, Santa Cruz, CA) for 48 hrs at 4oC with constant gentle shaking.
Following the completion of this incubation, the sections were rinsed and permeabilized followed by
incubation in biotinylated donkey anti-goat IgG secondary antibodies (1:200, Cat. # 708-065-003,
Jackson Immunoresearch, West Grove, PA) for 2.5 hrs at room temperature. The sections were
rinsed and permeabilized and incubated in ABC solution (1:100, Cat. # PK-4000, Vector Labs,
Burlingame, CA) for 1 hr at room temperature with constant gentle shaking. Following incubation
with ABC solution, the sections were rinsed three times in Tris buffer for 15 min. each. Following
these rinses, fos was visualized by incubation in a solution of 10 mg 3’,3’-diaminobenzidine with 7
µL of 30% H2O2 in Tris buffer. The reaction was stopped after 4.5 min by transfer of the sections
to Tris buffer. The sections were mounted on chrome-alum gelatin coated slides and dehydrated
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through successive ethanol washes followed by a wash in xylene. The slides were coverslipped using
Permount mounting medium (Fisher, Pittsburgh, PA).
Localization of c-fos immunoreactivity was evaluated using bright-field microscopy using an
Olympus BH2 microscope. Quantification of Fos-positive cells in the T2 dorsal horn (Laminae I-V)
was performed by counting dark brown nuclei in a 200 µm2 area of each animal. Data were then
grouped and averaged for each experimental category. The number of immunoreactive cells in the
dorsal horn was expressed as cells per square micrometers.
Statistical analysis. All data are presented as means (±SD). SigmaStat 3.1 (Systat Software) with
two-way analysis of variance with post hoc comparisons (Holm-Sidak test) was used to test for
interactions between SCS and neural ablation (C6 dorsal column transaction or cervical vagotomy)
and for interactions between SCS and cervical vagotomy versus atropine blockade for modulation of
infarct size. One-way analysis of variance with post hoc comparisons (Holm-Sidak test) was used
for hemodynamic data and for effects of selective adrenergic blockade on infarct size. A significance
of P < 0.05 was used. Summary data for Fos-positive cells were compared using a two-way ANOVA
with the Holm-Sidak test for pair-wise comparisons (significance at p<0.05).

RESULTS
Hemodynamic variables. Table 1 summarizes heart rate and blood pressure changes identified
in each of the four non-SCS experimental groups. For sham SCS control, dorsal column transection
control and cervical vagotomy control groups, heart rate was no different during baseline, coronary
artery occlusion or reperfusion. For the atropine control group (without C1-C2 SCS), heart rate
decreased from baseline only in the later stages of reperfusion. Baseline blood pressures were
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similar in all four groups of animals. During coronary artery occlusion, blood pressure was
significantly decreased from baseline for all groups except vehicle control. For all four groups,
blood pressure was decreased significantly from baseline at 1 hour reperfusion.

Table 2 summarizes heart rate and blood pressure for animals with pre-emptive C1-C2 SCS
with selective autonomic receptor blockade. For the vehicle-treated group, there were minor
increases in heart rate associated with C1-C2 SCS and during the subsequent addition of the cardiac
ischemic stress. In the vehicle control group, blood pressure was reduced significantly from post“block” baseline values during coronary artery occlusion and reperfusion. For selective autonomic
blockade, pretreatment with prazosin reduced basal mean blood pressure, which was sustained
throughout the succeeding observation periods. Pretreatment with atenolol reduced heart rate
significantly and pretreatment with atropine increased heart rate significantly; these changes were
sustained throughout the subsequent observation periods. With the exception of the prazosin
group, blood pressure decreased during coronary artery occlusion and reperfusion.
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Heart rate was minimally affected from baseline values during C1-C2 SCS (Tables 2 and 3).
Neither was it different during coronary artery occlusion or reperfusion in animals undergoing either
C6 dorsal column transection or cervical vagotomy (Table 3). Within group comparisons indicate
that C1-C2 SCS by itself had no significant effect on heart rate or blood pressure. In all groups,
blood pressure declined slightly from baseline during the C1-C2 SCS + coronary occlusion, with
significant reductions from baseline occurring during reperfusion in all three groups (Table 3).

41

Effects of C1-C2 SCS on Infarct size. Body weight and left ventricular risk zones were similar in
all experimental groups (data not shown). Figure 2 summarizes infarct sizes (expressed as a
percentage of the zone at risk) quantified in rabbits with intact neuroaxis (cord intact) that were
subjected to 30-min. periods of regional ischemia in the absence of SCS (Sham SCS) vs. those with
pre-emptive C1-C2 SCS. These data were compared to data obtained from similar groups following
C6 dorsal column transection 1 hr prior to the onset of SCS-coronary artery occlusion (Protocols 13 in Figure 1). There was a significant change in infarct size when comparing different cord status
(intact versus C6 dorsal column transaction) vs. the absence or presence of SCS (p=0.036) with cord
status.
Figure 2. Infarct size (percentage of
risk zone) for sham SCS rabbits
without (cord intact) and with C6
dorsal column transection compared
to rabbits with pre-emptive C1-C2
SCS without (cord intact) and with
C6 dorsal column transection. For
each group, individual animals are
shown along with mean ± SD data
for each group (open triangle and
vertical bar). # p<0.05 for
innervations state (cord intact versus
C6 dorsal column transection),
without (sham) and with pre-emptive
C1-C2 SCS. * p<0.05 for SCS
factor, intact versus C6 dorsal
column transection.
In sham animals, ventricular infarct size averaged 43.8 + 6.9% of tissue volume. This index
was unaffected by prior C6 dorsal column transection (47.6 ± 14.7%; Fig. 2, column 2). With the
spinal cord intact, pre-emptive C1-C2 SCS decreased infarct size to 25.2 + 10.7% (Fig. 2, column 3;
significant reduction compared to Sham SCS controls). The efficacy of pre-emptive C1-C2 SCS to
reduce infarct size in response to the 30 min. ischemic stress was eliminated after C6 dorsal column
transection (Fig. 2, right hand columns infarct size = 42.8 + 9.4%). The ability for pre-emptive C142

C2 SCS to reduce infarct size was also eliminated by pretreatment with prazosin (40.0 + 9.4%),
atenolol (40.2 + 11.1%), or yohimbine (36.8 + 10.3%) (c.f., Fig. 3). In total, these data indicate the
ability of pre-emptive C1-C2 SCS to modify sympathetic efferent function via intersegmental
projections to the thoracic cord.
Figure 3. Infarct size
(percentage of risk zone) for
sham controls compared to
rabbits with pre-emptive C1C2 SCS with intact neuroaxis
(vehicle) or following
selective adrenergic receptor
blockade with α1 (prazosin),
β1 (atenolol) or α2
(yohimbine) pretreatment
(c.f. Fig. 1, protocol 2). For
each group, data for
individual animals are shown
along with mean ± SD data
for each group (open triangle
and vertical bar). * p<0.05
from all other groups.
Neither atropine nor cervical vagotomy alone (c.f., in the absence of SCS) affected infarct
size induced by CAO/ 3 hr reperfusion (Fig. 4, c.f., middle columns of both groups). Moreover, the
capacity for pre-emptive C1-C2 SCS to reduce infarct size was unaffected by cervical vagotomy (23.6
+ 11.1%) compared to vehicle control (25.2 + 10.7%) (Fig. 4). In contrast, pretreatment with
atropine 15 min. prior to the onset of pre-emptive SCS (protocol 2) eliminated its infarct reducing
effects (51.6 + 8.6%).
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Figure 4. Infarct size (percentage of
risk zone) in sham controls compared
to that of rabbits pretreated with the
muscarinic blocker atropine or cervical
vagotomy, as compared to animals
exposed to pre-emptive C1-C2 SCS
with 1) intact neuraxis (control SCS), 2)
following cervical vagotomy, or 3)
muscarinic receptor blockade
(atropine). For each group, individual
animal data are shown along with mean
± SD data for each group (closed
diamond and vertical bar). # p<0.05
for treatment (none, cervical vagotomy
or atropine) with and without preemptive C1-C2 SCS. * p<0.05 (with
pre-emptive C1-C2 SCS) for atropine pre-treatment versus control or cervical vagotomy.
Effects of C1-C2 SCS on ventricular arrhythmogenic potential. Ventricular fibrillation secondary to
myocardial ischemia occurred in 22% of control animals (sham SCS) with 11% experiencing sudden
cardiac death (SCD) (Table 4). Across all groups, VF occurred preferentially in the first ½ of the
ischemic insult with no stratification with respect to those that showed spontaneous conversion
back to sinus rhythm versus those that did not recover, e.g. SCD. Incidence of CAO-induced VF
increased to 36% in animals with prior vagotomy or C6 dorsal column transection, with incidence of
SCD of 18% for both groups (Table 4). Pretreatment with atropine showed similar responses to
control.
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In animals with C1-C2 SCS, pretreatment with cholinergic or adrenergic antagonists, along
with selective neuroablation, modified the incidence of CAO-induced VF and subsequent events of
SCD (Table 4). C1-C2 SCS by itself did not alter the incidence of either VF or SCD. Prior C6
dorsal column transection however, increased the lethality of CAO. In contradistinction to sham
SCS animals, prior cervical vagotomy completely eliminated the incidence of CAO-induced VF.
Such was not case with atropine pretreatment where CAO applied during SCS resulted in a 33%
CAO-induced VF with 11% subsequent SCD. Pretreatment with alpha adrenergic blockade was
associated with substantial increases in events, especially following α2 blockade, with the incidence of
CAO-induced VF increasing to 92%; 50% of such animals having SCD. In contrast, prior treatment
with the β1 adrenergic selective blockade (atenolol) completely eliminated CAO-induced VF. These
data point to the dynamic interactions between adrenergic and cholinergic control of cardiac
electrical stability in ischemic stress.
Effects of C1-C2 SCS on thoracic dorsal horn activity. The effects of CAO on cFosimmunoreactivity in the dorsal horns (Laminae I-V) of the T2 spinal cord were examined to
determine how spinal cord neurons transduce the effect of CAO in the absence and presence of C1C2 SCS (Figure 5). Coronary artery occlusion (CAO) increased activation of the laminae I-V
neurons in the high thoracic spinal cord. CAO increased this index from 7.19±3.50 Fos-positive
cells per 200 µm2 in control states to 19.36±5.46 cells per 200 µm2. C1-C2 SCS alone increased this
activation index in dorsal horn neurons of the high thoracic spinal cord to a lesser degree when
compared to control states (9.73±4.82 cells per 200 µm2). In the presence of C1-C2 SCS, CAOinduced activation of dorsal horn neurons was reduced when compared to animals subjected to
CAO alone (3.18±1.83 cells per 200 µm2; p=0.028).
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ANOVA with the Holm-Sidak post hoc comparison.

Figure 5. Activation of neurons in the
thoracic spinal cord in response to
ischemia. C-fos expression was
measured in dorsal horns (laminae I-V)
of the upper thoracic spinal cord.
Coronary artery occlusion (CAO) caused
an increase in the activation of spinal
neurons. Following SCS, this increase
was lessened indicating reduction in
cardiac afferent neuronal activation.
SCS applied prior to and during CAO
caused a greater (significant) reduction
in dorsal horn spinal neuronal activation.
* indicates p<0.05 using two-way

Discussion
This study demonstrates for the first time that pre-emptive electrical neuromodulation
therapy applied to the cranial cervical spinal cord reduces the size of infarcts induced by transient
myocardial ischemia. It further indicates that disruption of intersegmental communication from C1C2 to T1-T4 cord neurons, by transection of the C6 dorsal column, prevents the infarct reducing
effect of C1-C2 electrical stimulation. Thus, a necessary difference in control is exerted by thoracic
cord neurons (Foreman et al., 2004; Foreman et al., 2000; Wu et al., 2008) versus cervical neurons,
given the potential of high cervical cord neurons to modify not only thoracic cardiac efferent
adrenergic neuronal outputs, but also vagal neuronal outflows to modulate infarct size in response to
the regional ischemia (Fig. 3).
Although cervical vagotomy did not affect the capacity of pre-emptive high cervical SCS to
modify infarct size, this does not preclude some involvement of peripheral cardiac cholinergic
neurons in these events since atropinization completely abolished the capacity of C1-C2 SCS to
reduce infarct size. Cervical vagotomy decentralizes parasympathetic inputs to the intrinsic cardiac
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nervous system (ICN) but still allows for spontaneous neuronal activity and intracardiac reflex
function (Ardell et al., 1991), whereas atropine interferes with both end-organ and neuronal
processing within the ICN (Armour, 2008). In other words, high cervical SCS affects ventricular
electrical stability via both sympathetic and parasympathetic efferent neurons.
There appears to be concurrent influences of alpha- and beta-adrenoceptor neurons in such
events since blockade of either receptor subgroup elicited diametrically opposed responses on the
incidence of sudden cardiac death. While β1-adrenoceptor blockade mitigated the potential for
sudden cardiac death, α1- and α2-adrenoceptor blockade enhanced (doubled or tripled, respectively)
that potential. In contrast, following cervical vagotomy while coronary artery occlusion alone was
associated with an increased incidence of sudden cardiac death, concurrent high cervical SCS (post
vagotomy) completely abolished ventricular fibrillation initiated during transient myocardial
ischemia.
With regards to neural responses to cardiac stress, electrical stimulation of the C1-C2 dorsal
column region is known to decrease the activity of spinothalamic tract neurons receiving cardiac
nociceptive sensitive inputs (Chandler et al., 1993; Foreman et al., 2004). It also decreases myocardial
ischemia evoked dorsal horn neuronal activation (Ding et al., 2008a; Ding et al., 2008b) and
substance P release from ischemia sensitive cardiac afferent neurons, while recruiting thoracic spinal
sympathetic neurons (Ding et al., 2008a; Ding et al., 2008b).
Cranial cervical cord information is transmitted to the lower segments of the spinal cord via
the dorsal columns, propriospinal pathways and/or supraspinal loops. C1-C2 SCS does not activate
supraspinal neurons, including those in brainstem nucleus tractus solitaries (Ding et al., 2008a; Ding
et al., 2008b; Qin et al., 2007). In fact, C1-C2 SCS or chemically-activated C1-C2 propriospinal
neurons suppress the responses of upper thoracic spinal neurons to noxious cardiac afferent input
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(Qin et al., 2004; Qin et al., 2008). C1-C2 SCS also inhibits substance P release from activated
ischemia sensitive cardiac afferent neurons (Ding et al., 2008b; Ding et al., 2008a). Thus, caudal
cervical dorsal column transection mitigates cranial cervical-mediated processing of noxious visceral
afferent inputs (Qin et al., 2007). These results are in accord with the finding that C6 dorsal columns
transection mitigates C1-C2 SCS ventricular infarct size reduction secondary to transient myocardial
ischemia. Such data indicate that spinal cord propriospinal descending projections or antidromic
activation of ascending fibers in the dorsal column influence high cervical inputs to the thoracic
spinal cord neurons.
Cervical cord neuromodulation of ischemia-induced myocardial infarction. Adrenergic receptors
modulate both cardiomyocytes and neurons that regulate them (Armour, 2008; Ardell, 2004). Thus,
infarct size can be influenced via α-receptor coupled PKC pathways as well as β-adenoreceptor
coupled PKA and p38 MAPK pathways (Yellon & Downey, 2003; Tsuchida et al., 1994; Sanada &
Kitakaze, 2004). In fact, high thoracic SCS activates cardiomyocyte PKC (Southerland et al., 2007).
Furthermore, the capacity of C1-C2 SCS to reduce infarct size can be eliminated by α or β1
adrenergic blockade. In other words, intersegmental spinal cord interactions may impart
cardioprotection, in part, via cardiac adrenergic efferent neurons.
In the current study, cervical vagotomy did not change C1-C2 SCS-mediated reduction in
infarct size while atropine eliminated it. Cholinergic receptors influence cardiomyocytes directly and
indirectly via the cardiac neuroaxis (Armour, 2008; Ardell, 2004). The minimal impact of vagotomy
on C1-C2 SCS-induced infarct size reduction may reflect at least three factors: 1) the lack of
contribution of C1-C2 SCS evoked activity on supraspinal projections to the nucleus tractus
solitaries (Ding et al., 2008a; Ding et al., 2008b), thereby minimally effecting parasympathetic efferent
neuronal outflow to the heart; 2) maintenance of parasympathetic efferent neuronal outflow changes
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from the intrinsic cardiac nervous system post-cervical vagotomy (Ardell et al., 1991; Huang et al.,
1993; Murphy et al., 2000); and 3) the function of intrathoracic reflexes, including those on the heart
(Foreman et al., 2000; Armour et al., 2002; Ardell et al., 2009).
Neuromodulation therapy and arrhythmias. These data provide important insights into putative
interactions that occur among peripheral and central aspects of cardiac neuroaxis and its impact on
electrical stability of the ischemic heart. Pre-emptive thoracic SCS is known to impact afferent
(Foreman et al., 2004; Chandler et al., 1993; Ding et al., 2008a; Ding et al., 2008b), efferent
(Southerland et al., 2007; Olgin et al., 2002; Ardell et al., 2009) and local circuit neuronal (Cardinal et
al., 2006; Armour et al., 2002; Ardell et al., 2009) processing within brainstem, spinal cord, and
peripheral nodes of the cardiac neuroaxis. When specific elements of this neuronal hierarchy for
cardiac control are altered, control of cardiac function may become compromised (Armour, 2008).
For instance, the increased incidence of myocardial ischemia-induced sudden cardiac death
identified following C6 dorsal column transection may reflect a loss of descending inhibitory
restraints on spinal cord sympathoexcitatory reflexes (Ardell et al., 1982). Correspondingly, the
increase in myocardial ischemia-induced sudden cardiac death post α2-adrenoceptor blockade may
be reflective of imbalances in neurotransmitter release secondary to loss of negative feedback on
neurotransmitter release from autonomic efferent postganglionic neurons (Xu & Adams, 1993;
Adams & Cuevas, 2004). With respect to α1-adrenoceptor blockade and a resultant loss of
background excitation of subpopulations of intrinsic cardiac neurons (Armour, 1997; Ishibashi et al.,
2003; Richer et al., 2008), subsequent reflex activation derived from ischemia-sensitive afferent
neuronal inputs may asymmetrically modify efferent neuronal outputs such that any arrhythmogenic
substrate becomes enhanced.

49

The abolition of myocardial ischemia-induced sudden cardiac death post-vagotomy in the
presence of high cervical SCS seems to be counter-intuitive to the documented anti-arrhythmogenic
effects of enhanced parasympathetic efferent neuronal activity (Vanoli et al., 2008; Schwartz, 2001).
It should be noted that imbalances in cardiac sympathetic and parasympathetic control initiated by
ischemia can be mitigated by: 1) interrupting parasympathetic preganglionic neuronal inputs (postvagotomy) (Huang et al., 1993); and 2) the stabilizing effects of SCS on the intrinsic cardiac nervous
system (Armour et al., 2002; Foreman et al., 2000).
Fos expression is an indicator of cellular activation in the spinal cord as manifested, in this
instance by cardiac afferent neuronal activation secondary to cardiac ischemia transduction (Hua et
al., 2004; Ding et al., 2008a). Ischemia activates populations of the cardiac afferent neurons, as
indicated by increased Fos expression in the high thoracic spinal cord dorsal horn, specifically
laminae I-V, as reported in other studies (Hua et al., 2004). Such afferent neuronal activation to the
spinal cord, secondary to myocardial ischemia transduction, also occurs following application of
noxious stimuli to afferent neuronal inputs to lower thoracic and lumbar spine (Qin et al., 2007).
Myocardial ischemia activation of cardiac afferent neuronal inputs to the spinal cord and higher
centers (Hua et al., 2004; Ding et al., 2008a) may initiate deleterious reflexes (Hua et al., 2004; Ding et
al., 2008a), thereby indirectly modifying cardiac function. Any ability to moderate such reflexes may
moderate such adverse effects.
Neuromodulation of the spinal cord at a level higher (C1-C2 SCS) than the incoming cardiac
sympathetic afferent neuronal inputs (T1-T5) demonstrates that intersegmental interactions that
sub-serve reflex processing can occur within and between various levels of the spinal cord. Thus,
these data support the thesis that high cervical spinal segments of the spinal cord may not only act as
a coordinating center for visceral organ afferent inputs traveling centrally but also display a capacity
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to modify sympathetic efferent control of visceral organs (Qin et al., 2007; Ding et al., 2008b; Ding et
al., 2008a).
Perspectives and significance
High cervical SCS stabilizes reflex processing within the cardiac neuroaxis to reduce infarct
size and the potential for ischemia-induced sudden cardiac death, doing so via modulating not only
efferent adrenergic outflow, but also cholinergic outflow to the heart (Fig. 6). These data also
indicate that cervical SCS neuromodulation therapy targets multiple nodes of the cardiac neuroaxis,
namely both sympathetic and parasympathetic efferent outflows to the heart. That C6 dorsal
column transection and cervical vagotomy exerted differing effects on myocyte viability postischemia or even evoked sudden cardiac death point to the importance of understanding the
multiple interactions existing within the various nodes of the cardiac neuroaxis. This was made
evident by the fact that β-adrenergic blockade, while reducing the risk for myocardial ischemiainduced sudden cardiac death, obtunded any infarct size reduction capability of SCS. It is only by
understanding the interactions that occur among peripheral and central nodes of the cardiac
neuroaxis that appropriate therapies targeting select neuroaxis components can evolve.
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Figure 6. Schematic of proposed interactions that occur within and among intrathoracic autonomic
neurons and between them and central neurons. Intrinsic cardiac ganglia possess afferent neurons,
sympathetic (Sympath) and parasympathetic (Parasym) efferent neurons and interconnecting local
circuit neurons (LCN). Extracardiac intrathoracic ganglia contain afferent neurons, local circuit
neurons and sympathetic efferent neurons. Neurons in these intrinsic cardiac and extracardiac
networks form separate and distinct nested feedback loops that act in concert with CNS feedback
loops involving the spinal cord and medulla to coordinate regional cardiac function on a beat-tobeat basis. Symbols: Aff., afferent; DRG, dorsal root ganglia; Gs, stimulatory guanine nucleotide
binding protein; Gi, inhibitory guanine nucleotide binding protein; AC, adenylate cyclase; beta-1
adrenergic receptor; M2- muscarinic receptor.
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Abstract
This study evaluated whether electrical neuromodulation therapy applied to the rostral
thoracic spinal cord affects the capacity of cardiac first order afferent neurons to transduce
myocardial ischemia. We recorded the transduction characteristics of left ventricular primary
afferent neuronal somata in nodose and dorsal root ganglia (DRG) in situ in response to exposing
their sensory neurite fields to chemical stimuli versus regional ventricular ischemia (transient left
anterior descending [LAD] coronary artery occlusion). Epicardially applied veratridine activated
both sensory populations, as did transient ventricular ischemia. After 20 min. of spinal cord
stimulation (SCS: 50 Hz, 200 ms duration, 90% motor threshold applied to dorsal columns of T1-T3
spinal segments) the ischemia-induced depression of left ventricular chamber dp/dt was mitigated.
SCS likewise attenuated the capacity of both sensory populations to transduce local ischemia. Yet,
SCS did not directly (antidromically) activate somata of either population. It is concluded that while
SCS does attenuate ischemia-induced enhancement of nodose and dorsal root ganglion ventricular
sensory neurons, this is reflective of an altered milieu surrounding their neurites rather than direct
(antidromic) somata effects. These data further imply that while such neuromodulation therapy can
alter cardiac afferent response to transient MI, such alterations are secondary to changes in the
transduction of cardiac milieu rather than suppression of the afferents’ capacity to transduce that
milieu.
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Introduction
A pressing issue with respect to spinal cord stimulation therapy (SCS) in the treatment of
myocardial ischemia (MI) remains whether if such therapy obtunds the capacity of cardiac primary
afferent neurons to transduce MI (Foreman and others 2004; Mannheimer and others 2002). If
blunting of the transduction capabilities of the cardiac neuroaxis to transduce an ischemic event
does indeed occur, that might negate the clinical usefulness of SCS because the patient would no
longer become aware of critical ischemic episodes (Armour 2008). Cardiac afferent neurons,
distributed throughout nodose and cranial thoracic dorsal root ganglia (DRG), transduce a
constantly changing cardiac mechanical and chemical milieu (Armour 1999; 2004). The neurites of
cardiac afferent neurons are activated by a number of chemicals, including those known to be
released from the ischemic myocardium: c.f., adenosine and peptides such as bradykinin and
substance P (Armour and Kember 2004). It is well recognized that nodose and DRG cardiac
afferent neurons exert major influences via the cardiac neuroaxis on regional cardiac dynamics via
reflex modification of both sympathetic and parasympathetic efferent outflows (Ardell 2004;
Armour 1999; 2004).
Neuromodulation applied to select nodes of the cardiac neuroaxis (e.g. SCS applied at T1-T3
spinal levels) is known to mitigate excessive MI-induced reflex activation of extracardiac (Ardell and
others 2009) and intrinsic cardiac neurons (Foreman and others 2000). SCS does so without
interrupting direct autonomic efferent projections to the heart (Cardinal and others 2006). It has
been proposed that SCS modulates sensory transduction of the ischemic myocardium to neurons in
the thoracic spinal cord dorsal horn (Qin and others 2008). SCS has been demonstrated to
modulate the response of second order neurons within the spinal cord to ischemia (Qin and others
2008). Conversely, recent evidence has suggested that SCS directly activates DRG afferent neurons
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to increase their release of neurotransmitters into peripheral tissues from their sensory neurites,
imposing an efferent function on afferent neurons (Linderoth and others 1994). In fact, it has been
proposed that this afferent/efferent function could be a primary mechanism whereby SCS exerts its
clinical benefits to the cardiac patient (Linderoth and others 1994). However to date, the effects of
SCS on first order cardiac afferent neurons has not been assessed.
To evaluate whether such SCS neuromodulation therapy does indeed blunt a patient’s
capacity to sense an ischemic event, we sought to determine: 1) whether SCS alters the capacity of
first order cardiac sensory neurons to transduce MI and, if that is the case, 2) whether that occurs via
direct antidromic modification of first order afferent neuronal somata or 3) indirectly by altering the
milieu surrounding their cardiac sensory neurites.

Materials and Methods
Animal preparation: Mongrel dogs (n=41; either sex), weighing 17.1-28.0 kg, were used in this
study. All experiments were performed in accordance with the guidelines for animal
experimentation described in the “Guiding Principles for Research Involving Animal and Human
Beings” (Society 2002). The Institutional Animal Care and Use Committee of the East Tennessee
State University approved these experiments.
Animals were pre-medicated with sodium thiopental (25 mg/kg, i.v., supplemented as
needed), intubated and maintained under positive-pressure ventilation. Isoflurane (2%) was used as
the anesthetic agent during surgery. Following surgery, the anesthesia was switched to α-chloralose
(75 mg/kg i.v. bolus, with repeat doses of 12.5 mg/kg i.v., as required). Heart rate and blood
pressure were continuously monitored with depth of anesthesia determined by monitoring corneal
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reflex, jaw tone, and hemodynamic parameters. Body temperature was maintained via a circulating
water heating pad (Gaymar T/Pump, Gaymar Industries Inc., Orchard Park, NY).
The left femoral artery and vein were catheterized to monitor blood pressure and deliver
anesthetic agents throughout the experiment. The right femoral artery was catheterized and a
Mikro-Tip Pressure Transducer Catheter (Millar Instruments, Houston, TX) was advanced into the
left ventricular (LV) chamber. Heart rate was monitored via a Lead II electrocardiogram. These
indices, along with concurrent afferent neuronal activity (see below), were digitalized (Power 1401,
Cambridge Electronic Design, Cambridge, England), stored and analyzed offline by the Spike2
(Cambridge Electronic Design, Cambridge, England).
Spinal cord stimulation (SCS): Two different protocols for SCS electrode placement were used,
depending on the site of afferent recording. With respect to experiments for recording nodose
activity, animals were first placed in the prone position and the spinal epidural space was penetrated
percutaneously with a Touhy needle through a small skin incision in the T6 spinal level. An eightpole lead (Octrode, Advanced Neuromodulation Systems, Plano, TX) was advanced rostrally in the
epidural space to the T1-T3 spinal cord level. The tip of the lead was positioned slightly to the left of
midline under fluoroscopy. Consistent with current clinical practice (Augustinsson and others
1995), the rostral pole was positioned at T1 and the caudal pole was positioned at T3 level. With
respect to DRG neuronal activity recordings, a laminectomy was performed removing the dorsal
spinal processes of the C8-T6 vertebrae and the eight-pole lead was laid directly on the dorsal aspect
of the T1-T3 spinal cord. In both cases, proper electrode placement was determined by delivering
electrical current to the spinal cord dorsal horn via the rostral (cathode) and caudal (anode) poles of
the electrode using a PSIU6 constant current isolation unit (Grass Instruments, Quincy, MA)
connected to a Grass S88 stimulator (Grass Instruments, Quincy, MA). Motor threshold (MT)
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intensity was determined as the lowest current that induced muscle contractions in the proximal
forepaw and shoulder. For nodose ganglion recordings, following SCS electrode implantation the
animals were rotated to the supine position, with MT being rechecked in this position. In each
experimental protocol, SCS was delivered for 20 min. at 50 Hz, 200 µs duration and at a current
intensity of 90% MT (range 0.25-2.8 mA, mean 0.98±0.19 mA). MT was checked periodically
during the experiments. MT did not vary significantly from initial levels throughout each
experiment.
Afferent neuronal activity recording: Activity generated by neuronal somata in the nodose ganglia
of 20 animals vs. neuronal somata in the DRGs in 21 animals was recorded in situ, using methods as
reported previously (Gagliardi and others 1988). Briefly, for nodose ganglion recordings, the
animals were placed in the prone position and an incision was made in the ventral neck to expose
the nodose ganglia. The tissue surrounding the nodose ganglia was left intact to stabilize it during
prolonged recording of the activity generated by neuronal somata therein. With respect to recording
DRG somata activity, animals were placed in a supine position and after laminectomy (C8-T6) the
T1-T4 DRG ganglia were exposed.
For either DRG or nodose neurons, a tungsten microelectrode (250 µm diameter and
exposed tip of 1 µm; impedance of 9-11 MΩ at 1000 Hz), mounted on a micromanipulator, was
lowered into respective ganglia using a microdrive. Each ganglion was explored and electrical signals
so derived were led into a differential preamplifier (BMA-831, CWE Inc., Ardmore, PA) with a high
impedance head stage (band width set at 300 Hz to 10 kHz). Signals were further amplified by a
battery-driven pre-amplifier (5113 Pre-Amp, Signal Recovery, Oak Ridge, TN) (band width 100 Hz
to 2 kHz). Amplified neuronal signals, together with recorded cardiovascular indices, were digitized
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(Cambridge Electronics Design, power 1401 data acquisition system), stored, and analyzed using the
Spike 2 software package (Cambridge Electronics Design).
Neuronal activity was identified as action potentials with signal to noise ratios greater than
3:1. The activity generated by individual neuronal somata in either the nodose or DRG ganglia was
identified by the amplitude and configuration (waveform recognition) of these recorded action
potentials using the Spike 2 program. Using these techniques and criteria, action potentials
generated by individual somata and/or dendrites, rather than axons of passage, can be recorded for
extended periods of time (Gagliardi and others 1988).
Protocols employed: Gauze soaked in solutions of the following chemicals: veratridine (100
µM), bradykinin (100 µM), adenosine (100 µM), or substance P (10 µM) were first applied to the
surface of the ventral left ventricle to test whether recorded nodose or DRG soma transduced
cardiac stimuli. After waiting 1 min., the chemical-soaked pledge was removed and the pericardium
flushed with normal saline. If none of the DRG or nodose ganglion neurons were activated by
these chemicals, the microelectrode was moved until an active site was identified that consistently
responded to chemical activation of the LV sensory neurites. Once such a subset of nodose or
DRG neurons was identified, the left anterior descending (LAD) coronary artery was occluded for 1
or 2 min by means of a silk ligature snare placed around that vessel at the level of its first diagonal
branch. If coronary artery occlusion (CAO) did not evoke changes in primary afferent activity, the
electrode was moved to another recording site. Once a population of LV afferent neurons was
identified which responded first to chemicals and then to LAD CAO, animals were randomized to
receive either pre-emptive SCS (50 Hz, 200 µs, 90% MT) for 20 min or sham SCS for 20 min and
the LAD CAO stress repeated. In a separate group of 3 animals with DRG recordings, the dorsal
roots were sectioned between identified ganglia and the spinal cord; all other DRG were left intact.
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Thereafter, the capacity of neuronal somata therein to transduce myocardial ischemia was studied
before and after SCS.
Suprathreshold SCS: In a subset of animals (n=5), we evaluated the potential of spinal cord
stimulation to modify identified DRG neural activity antidromically. A short-acting competitive
neuromuscular blocker, rocuronium bromide (1 mg/kg; time to onset 2-4 min. with clinical duration
of action of 20 min. (Sparr and others 2001)), was used to temporarily prevent spinal cord
electrically induced motor movement. For these experiments, the frequency of spinal cord
stimulation ranged from 0.1 to 5 Hz and the voltage employed ranged from motor threshold to 2.5x
motor threshold. For these experiments, alpha chloralose (8-12 mg/kg) was temporarily increased
prior to neuromuscular blockade and maintained at that level during subsequent supra-motor
threshold stimuli.
Data analysis: Action potentials arising from a nodose or dorsal root ganglion site were
characterized by means of differences in their amplitudes and configurations, employing waveform
recognition analysis (Spike2 program). Neuronal activity changes elicited during each intervention
were evaluated by comparing activity generated immediately before chemical application or
occlusion with data obtained during and following (e.g. reperfusion) those interventions. Average
activity data are presented as impulses per second. Antidromic responses to SCS were quantified by
spike-triggered averages of afferent neuronal activity during the progressive suprathreshold
stimulation protocols, the spike derived from delivery of electrical pulses to the SCS electrode. All
data are expressed as means ± SEM. SigmaStat 3.1 (Systat software) with 2-way ANOVA with posthoc comparisons (Holm-Sidak method) was used to test for differences between groups. A
significance of p< 0.05 was used for these data analyses.
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Results
Hemodynamic data: Since both groups generated similar hemodynamic changes during LAD
coronary artery occlusion (CAO), CV indices obtained during nodose and DRG studies were
grouped together. Before SCS, MI induced a significant increase in heart rate (115±9 to 130±9
beats/min; p<0.05). CAO in control states likewise did not significantly change left ventricular
systolic pressure (140±4 - 134±4 mm Hg; ns) or mean arterial blood pressure (134±6 – 129±6 mm
Hg; ns). However, CAO did reduce +LV dp/dt (1999±98 to 1852±96 mmHg/sec; p<0.01) and –
LV dp/dt (-2755±340 to -2159±320 mmHg/sec; p<0.02). SCS by itself did not change any
recorded CV variable. Following SCS, the major change in CAO-induced hemodynamic responses
was that +LV dp/dt (control: 2037±83 mmHg/s vs. 1976±53 mmHg/s; ns) was significantly altered
during the ischemic stress. In contrast, the LV dp/dt depression was maintained with repeated
occlusions.
Dorsal root ganglion afferent neuronal activity: The activity generated by identified DRG neurons
increased during epicardial veratridine application (0.4±0.2 to 2.9±0.6 imp/s). Subsequent ischemic
challenge evoked a brisk increase in neuronal activity, especially at the transition points between
normal flow and ischemia (e.g. onset and release). Fig. 1 demonstrated that the duration of transient
MI-induced activity exceeds the duration of the ischemic insult. Overall, LAD CAO increased
average DRG activity (0.6±0.2 to 2.7±0.8 imp/s; p<0.02) with even greater activity levels observed
during reperfusion (4.9±2.6 imp/s; p>0.05 from control and ischemic states; c.f., Figs. 1 & 2). The
average recovery from peak activity to baseline of the evoked response in DRG activity to a 1 min
LAD CAO was 207±35 s. Enhancement of DRG activity in response to repeated LAD CAO (time
control) remained stable (415 % increase, LAD CAO 1 versus 570% increase, LAD CAO 2).
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Recovery of evoked responses from peak activity to baseline was likewise maintained in time
controls (180±49 s for first LAD to 220±135 s for second LAD).

Figure 1: DRG neuronal activity recorded in response to 1 min. LAD CAO. LAD CAO increased
DRG afferent neuronal activity, activity increasing further during reperfusion. DRG neuronal
activity was also grouped into 10 second segments to display average rate changes over time (3rd
trace). LVP = Left ventricular pressure. HR = Heart rate.
SCS mitigated increases in DRG afferent neuronal activity evoked by LAD CAO (Fig. 2).
While in control states LAD CAO increased their activity (0.6±0.2 imp/s to 2.7±0.8 imp/s
(p<0.02)), following SCS the MI-induced stressor no longer changed DRG activity (0.4±0.3 to
0.5±0.2 imp/s (ns)). After SCS, the reperfusion phase was also associated with reduced activity
(0.6±0.4 imp/s). In the 3 dogs in which the recorded dorsal root ganglia was acutely decentralized
from the spinal cord, SCS still reduced the LAD CAO-induced activation of the primary cardiac
afferent neurons within these ganglia (290% increase from baseline of 0.5±0.3 imp/s to 33%
increase from baseline of 0.3±0.2 imp/s post SCS). For this experiment, DRG located rostral and
caudal to the recorded ganglia and all contralateral DRG remained connected to the spinal cord.
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Figure 2: Activity
generated by DRG
neurons recorded during
baseline, LAD CAO and
reperfusion, peak activity
being achieved during
reperfusion. Following
SCS, the capacity of these
neurons to transduce
ventricular ischemia and
subsequent reperfusion
was reduced. * p<0.05
comparing baseline and
ischemia data during
before SCS; + p<0.05
post-SCS, comparing
control and ischemia data.
Nodose ganglion afferent neuronal activity: The activity generated by identified nodose ganglion
afferent neuronal somata increased during LAD CAO from 1.35±0.49 to 2.94±0.87 imp/s
(p<0.001), maintaining their enhanced state during reperfusion (Fig.3). Repeat LAD CAO elicited
similar neuronal responses. Nodose ganglion afferent neurons that responded to transient
ventricular ischemia were initially identified by their evoked response to chemical stimuli applied to
the LV epicardial ventral surface. Of the 34 ischemic-sensitive afferent neurons evaluated, 44%
responded to epicardial application of veratridine (0.8±0.2 to 3.5±1.2 imp/s; p<0.05), 44%
responded to bradykinin (0.7±0.5 to 3.2±1.0 imp/s; p<0.01), 24% to adenosine (0.6±0.1 to 1.3±0.3
imp/s; p0.01) and 35% to substance P (0.3±0.1 to 1.6±0.6 imp/s; p<0.03).
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Figure 3: Activity of
nodose ganglion afferent
neurons prior to, during
and after (reperfusion) 2
min. of LAD CAO.
Following SCS (right
columns) the ability of
ischemia to activate
nodose cardiac afferent
neurons decreased
significantly. * p<0.05
comparing ischemia to
baseline data in control.;
+ p<0.05 comparing
post- to pre-SCS data.

Following SCS, the capacity of nodose ganglion afferent neurons to transduce regional left
ventricular ischemia was reduced compared to control states (Fig. 3). During control states ischemia
enhanced nodose ganglion neuronal activity from 0.4±0.2 to 0.9±0.2 imp/s (p<0.05). Following
SCS, ischemia elicited only minor enhancement of their activity (0.2±0.1 to 0.3±0.1 imp/s; ns) (Fig.
3). Similarly, SCS obtunded nodose ganglion neuronal activation during the reperfusion phase
(0.9±0.3 imp/s versus 0.2±0.1 imp/s; ns). SCS also truncated the duration of nodose afferent
neuronal excitation in response to the 1 min ischemic stress (200±28 sec control vs 90±10 sec post
SCS; p=0.01).
DRG activity during supra-threshold SCS: To determine whether identified dorsal root ganglion
afferent neuronal somata could be antidromically activated by SCS, their activity was recorded as
SCS was applied at varying frequencies (0.5, 1 and 5 Hz) at intensities ranging from 90% MT to 2.5x
MT (Fig. 4). Spike-triggered averages of DRG activity, based upon delivered SCS pulses, were used
to quantify the potential for antidromic activation. No combination of frequencies or intensities of
stimuli evoked action potentials time-locked to the SCS pulses in identified ventricular afferent
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neurons indicating no antidromic activation of cardiac-related DRG neurons by SCS parameter sets
utilized.

Figure 4: In intact preparations, stimulation (frequency of 0.5 Hz) of the dorsal spinal cord with
different current intensities (MT, MT, 1.5x MT, 2x MT, and 2.5x MT) failed to activate identified
DRG cardiac afferent neurons (bottom trace). SCS = spinal cord stimulation. DRG activity =
dorsal root ganglion activity.

Discussion:
The results of this study demonstrate that the capacity of first order cardiac afferent neurons
(nodose and dorsal root ganglia) to transduce an ischemic myocardium is obtunded following
application of SCS. Previous work has indicated that SCS can suppress local circuit neurons in
peripheral ganglia without (Foreman and others 2000) interfering flow-through efferent pathways of
the sympathetic and parasympathetic nervous systems (Gibbons and others 2011). SCS likewise
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blunts ischemia-induced reflex activation of central and peripheral aspects of the hierarchy for
cardiac control (Ardell and others 2009; Foreman and others 2000; Qin and others 2008). This is
the first demonstration of SCS-mediated suppression of first order cardiac-related afferent inputs
and these effects are reflected on both DRG and nodose neurons.
Previous studies have demonstrated that SCS modulates the responsiveness of ischemiasensitive neurons located within the spinal cord related to both pain perception (Krames and
Foreman 2007; Qin and others 2008) and cardiovascular control (Ding and others 2008a; Ding and
others 2008b). The spinothalamic tracts carry nociceptive inputs from cardiac-related DRG neurons
to higher centers of the central nervous system (Krames and Foreman 2007; Qin and others 2008).
SCS likewise modulates reflex activation of peripheral aspects of the cardiac nervous system
(Armour and others 2002; Foreman and others 2000), a response likely related to suppression of
local circuit neurons (Gibbons and others 2011).
Cardiac nociceptive inputs project centrally via multiple pathways (Marieb 2004). Vagal
cardiac afferent neurons have their soma in nodose ganglia and project to nucleus tractus solitarius
neurons of the medulla (Marieb 2004) Dorsal root ganglia neurons project centrally to the dorsal
horn of the spinal cord and from there second order neurons project to other regions of the spinal
cord and supraspinal sites (Kuo and others 1984). As both populations (DRG and nodose) were
suppressed by SCS, it is unlikely that any suppressor effects can be ascribed to anti-dromic activation
of either population. That concept was confirmed by direct recording of the activity generated by
DRG neurons in the presence of low frequency SCS (c.f., no antidromic activation).
Ischemia is known to cause a decrease in myocardial contractility as indicated by a decrease
in LV dp/dt (Khalil and others 2005). The transient period of ischemia used in this study was
sufficient to cause a significant decrease in LV dp/dt. Following SCS, while basal contractile
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function was unaffected, transient LAD CAO failed to evoke a decrease in LV dp/dt. This finding
indicates that SCS reduced the stress to the myocardium resulting from transient myocardial
ischemia, a fact likely related to pre-emptive SCS rendering the myocytes downstream from the
occlusion ischemia-resistant.
In support of this concept, prior studies from our laboratory have demonstrated that both
high thoracic (Southerland and others 2007) and high cervical SCS (paper in press) reduce infarct
size to transient MI. Previous studies have demonstrated several intracellular mechanisms, i.e. α1–
PKC pathway and ß-PKA pathway, that cause the protection of myocytes against ischemic stress
(Southerland and others 2007; Yellon and Downey 2003). These intracellular mechanisms
themselves may play a significant role in the SCS-induced protection of the myocardium against
ischemic stress that was observed in this study (Wu and others 2008).
Previous investigators have suggested that SCS-mediated protection of peripheral tissues is
related to imposed efferent function on afferent projections, specifically to antidromic activation of
primary afferents with resultant release of neuropeptides to target tissues (Linderoth and others
1991). We found no corresponding data for first order cardiac-related afferents projecting centrally
in either the DRG or nodose ganglia. We further determined that if central projections to the
recorded DRG populations were selectively interrupted while maintaining all other DRG intact, high
thoracic SCS was still capable of truncating the MI-induced increase in neural activity. Together
with the antidromic experiment described above and the induced changes in LV dp/dt, these data
point to the importance of SCS-induced changes in myocytes themselves (e.g. rendering them
ischemic-resistant) as the primary mechanism for decreased afferent response to ischemic stress.
Perspectives and significance: Data derived from this study indicate that while SCS can modify
the stress of transient myocardial ischemia, as evidenced by its capacity to reduce the influence of
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myocardial ischemia on +LVdp/dt, it does not directly affect the capacity of cardiac afferent
neurons to transduce an ischemic event. We conclude that any neuronal modification so induced
was a consequence of their transduction of an altered ventricular milieu. Pain studies have suggested
that pre-emptive SCS renders cardiomyocytes ischemic resistant and this process involve alterations
in sympathetic efferent neuronal inputs to the heart (Southerland and others 2007). In the clinical
setting, patients are capable of tolerating increased levels of stress with SCS therapies (Mannheimer
and others 1993). However, when stressors reach a critical threshold, as indicated by indices such as
ST segment shift during a progressive exercise test (Mannheimer and others 1993), pain is perceived.
These data, in conjunction with that presented herein, demonstrate the increased ischemia resistance
exerted by neuromodulation therapies. This effect is likely reflective of induced changes in the
myocytes (Southerland and others 2007) and in the blunting of excessive MI-induced reflex
activation of efferents within the cardiac nervous system (Ardell and others 2009; Armour and
others 2002; Foreman and others 2000).
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Abstract
Our objective was to determine if atrial fibrillation (AF) results from excessive activation of intrinsic
cardiac neurons (ICNs) and, if so, whether select subpopulations of neurons therein represent
therapeutic targets for suppression of this arrhythmogenic potential. Trains of 5 electrical stimuli
(0.3-1.2mA, 1ms) were delivered during the atrial refractory period to mediastinal nerves (MSN) on
the superior vena cava to evoke AF. Neuroanatomical studies were performed by injecting the
neuronal tracer DiI into MSN sites that induced AF. Functional studies involved recording of
neuronal activity in situ from the right atrial ganglionated plexus (RAGP) in response to MSN
stimulation (MSNS) prior to and following neuromodulation involving either pre-emptive spinal
cord stimulation (SCS, T1-T3, 50 Hz, 200 ms duration) or ganglionic blockade (hexamethonium, 5
mg/kg). The DiI neuronal tracer labeled a subset (13.2%) of RAGP neurons, which also co-localized
with cholinergic or adrenergic markers. A subset of Dil labeled RAGP neurons were noncholinergic/non-adrenergic. MSNS evoked a ~4-fold increase in RAGP neuronal activity from
baseline which SCS reduced by 43%. Hexamethonium blocked MSNS evoked increases in neuronal
activity. MSNS evoked AF in 78% of right-sided MSN sites, which SCS reduced to 33% and
hexamethonium reduced to 7%. MSNS induced bradycardia was maintained with SCS, but mitigated
by hexamethonium. We conclude that MSNS activates subpopulations of intrinsic cardiac neurons,
thereby resulting in the formation of atrial arrhythmias leading to atrial fibrillation. Stabilization of
ICN local circuit neurons by SCS or the local circuit and autonomic efferent neurons with
hexamethonium reduces the arrhythmogenic potential.
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Introduction
Excessive activation of select inputs to the intrinsic cardiac nervous system (ICN) are known to
elicit atrial arrhythmias in normal (9; 22; 28) and pathophysiological states (11; 30). Discrete
activation of the axons in select mediastinal nerves can reproducibly elicit self-terminating periods of
atrial tachyarrhythmias/fibrillation (ATF) (9). Mediastinal nerves are made up of sympathetic and
parasympathetic efferent neuronal inputs into the intrinsic cardiac nervous system, as well as afferent
axons arising from cardiac tissues (9). They likewise contain interganglionic connections mediated
via local circuit neuronal projections (15) which sub-serve, in part, to coordinate peripheral reflex
function (7; 34). Because excessive activation of the axons in select mediastinal nerves reproducibly
elicits self-terminating periods of atrial tachyarrhythmias/fibrillation (ATF), this animal model has
been employed to study the neuropharmacological basis of neurally-evoked atrial arrhythmias (9;
28).
The extent of involvement of various ICN neuronal populations in mediating AF has yet to be
determined. Secondly, whether neuronally-induced atrial arrhythmias involve excessive activation of
select populations within the intrinsic cardiac neurons remains unknown. Since neuromodulation
therapy has been shown to suppress the ability of mediastinal nerves to induce AF (10), it has been
postulated that spinal cord stimulation (SCS) acts to suppress the responsiveness of the ICN to
excessive sensory inputs arising from the diseased myocardium in the induction of such arrhythmias
(10; 13). Likewise, pharmacological neuromodulation that blocks neuronal transmission within the
ICN has been shown to decrease the propensity of ATF formation secondary to mediastinal nerve
stimulation (9; 28). While these neuromodulation therapies are known to act upon the peripheral
autonomic nervous system (4; 13), how they target the ICN to reduce ATF formation initiated by
excessive mediastinal nerve stimulation has yet to be determined.
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To understand how neurons within the ICN respond to excessive inputs from extracardiac sources
(as mimicked by mediastinal nerve stimulation) in the induction of ATF, the present study was
designed to test the following hypotheses: 1) mediastinal nerve stimulation activates select neuronal
populations within the ICN in the induction of ATF; 2) stabilization of those populations within the
intrinsic cardiac nervous system via neuromodulation (electrical or pharmacological) blunts the
capacity of the ICN to respond to excessive inputs and thereby suppress its potential to induce atrial
tachyarrhythmias. This study identified the fact that excessive inputs to the ICNs in the induction of
ATF does indeed primarily involve excessive activation of local circuit neurons therein, sparing, for
the most part, direct efferent outflows to the heart.
Methods
Animal Preparation: Thirty mongrel dogs (either sex), weighing 18.6-26.9 kg, were used in this study.
All experiments were performed in accordance with the guidelines for animal experimentation
described in the “Guiding Principles for Research Involving Animal and Human Beings” (1). The
Institutional Animal Care and Use Committee of the East Tennessee State University approved
these experiments.
Neuronal Tracer Injection: Animals (n=2) were premedicated with sodium thiopental (15 mg/kg, i.v.),
intubated and anesthetized using 2% isoflurane. Heart rate and blood pressure were continuously
monitored (Surgivet Advisor Monitor, Smiths Medical) with depth of anesthesia determined by
corneal reflex, jaw tone, and hemodynamic parameters. Body temperature was maintained via a
circulating water heating pad (Gaymar T/Pump, Gaymar Industries Inc., Orchard Park, NY). Using
aseptic techniques, a right thoracotomy was performed at the 4th intercostal space; an incision was
made into the pericardial sac to expose the superior vena cava at the pericardial reflection into the
right atrium, and a pericardial cradle formed. Using techniques described previously (9; 28),
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mediastinal nerve projection sites were identified on the superior vena cava at the pericardial
reflection in which train electrical stimuli delivered during the atrial refractory period reproducibly
induced transient periods of atrial fibrillation. Ten μL boluses of 0.1 M solution of 1,1'-dioctadecyl3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) were then injected via a 1 cc Hamilton
syringe into that site. Following tracer injection, the pericardium and thoracic cavity were closed in
layers and residual air removed from the chest via a chest tube. Buprenorphine (0.01 mg/kg, i.m. or
i.v.) was administered pre- and post-operatively for pain management. Antibiotic therapy
(intramuscular cefazolin or oral cephalexin, 22 mg/kg) was administered twice daily prior to surgery
and continued for 2 days postoperatively. Animals were recovered for 2 days following surgery to
allow for transport of the tracer. The animals were re-anesthetized in the manner described above
and a thoracotomy performed to collect the right atrial ganglionated plexus (RAGP), an aggregate of
intrinsic cardiac neurons associated with control of atrial electrical and mechanical function (5; 27).
Immunohistochemistry: The RAGP cardiac ganglia were briefly washed in saline and then transferred to
a 4°C fixative solution containing 4% paraformaldehyde and 0.2% picric acid in phosphate buffered
saline (PBS, pH 7.3). Tissues were fixed at 4°C for 24 hr. They were then transferred to 20% sucrose
in PBS (4°C, 4 days) for cryo-protection, frozen on powdered dry ice, and stored in sealed tubes at 80°C until processed. The ganglia were sectioned at a thickness of 16 μm using a Leica CM 3050S
cryostat (Leica Microsystems Inc., Bannockburn, IL). Adjacent sections were collected on separate
chrome-alum gelatin coated slides such that six representative sets of tissue sections were obtained
from each tissue sample. Slide-mounted sections were stored in closed slide boxes at -20°C prior to
immunohistochemistry. Single- and double-labeling of sections were studied at room temperature
using standard methods previously described (19). Digitonin was used in solution instead of triton
X-100 to minimize loss of DiI during processing (24). Briefly, slides were rinsed with 0.1 M PBS
(pH 7.3), permeabilized in PBS containing 1000 μg/ml digitonin (Cat # 300411, EMD Biosciences,
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San Diego, CA) and 0.5% bovine serum albumin (BSA), and blocked for 2 hr in PBS containing
10% normal donkey serum (Cat # S30, Millipore, Billerica, MA), 1% BSA and 1000 μg/ml digitonin.
Tissues were then incubated overnight in a buffer containing either rabbit anti-Protein Gene
Product 9.5 (PGP 9.5, AB1761, Millipore, Billerica, MA) or various combinations of sheep antityrosine hydroxylase (TH, AB1542, Millipore, Billerica, MA), goat/rabbit anti-choline
acetyltransferase (ChAT, AB144P, Millipore, Billerica, MA /AB-N34, Advanced Targeting Systems,
San Diego, CA) or guinea pig anti-vesicular acetylcholine transporter (VAChT, AB1588, Millipore,
Billerica, MA). After washing with PBS, tissues were incubated for 2 hr with donkey anti-rabbit
secondary antibodies conjugated to AlexaFluor 488 and donkey anti-sheep secondary antibodies
conjugated to AlexaFluor 647 (A-21206, A-21448, Invitrogen, Carlsbad, CA) and washed with PBS.
Coverglasses were attached with Citifluor mounting medium (Ted Pella, Redding, CA) and sealed
with clear nail polish. Negative control slides were processed similarly without using primary
antibodies. The selectivity of fluorescence filters and the presence of co-localized markers were
confirmed in several sections obtained from each animal by sequential scanning with a Leica TCS
SP2 confocal microscope (Leica Microsystems Inc., Bannockburn, IL). The software used to
discriminate DiI-positive neuronal somata from background was ImageJ. This was performed on
images obtained by confocal microscopy. The neurochemical phenotype of DiI labeled neurons was
identified based on overlay confocal images.
Hemodynamic recording: In the remaining canines (n=28), animals were anesthetized and instrumented
for recording of neuronal activity from the RAGP ganglia. Responses (neural and atrial electrical
activity) to mediastinal nerve stimulation were evaluated prior to and following neuromodulation
using either ganglionic blockade (n=12) or spinal cord stimulation (n=16) (see below). Anesthesia
was maintained during surgery using 2% isoflurane with depth of anesthesia determined by corneal
reflex, jaw tone, and hemodynamic parameters. Following completion of the surgery, anesthesia was
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changed to α-chloralose (75 mg/kg i.v. bolus), with repeat doses (12.5 mg/kg i.v.) administered as
required throughout the duration of each study. Body temperature was maintained via a circulating
water heating pad (Gaymar T/Pump, Gaymar Industries Inc., Orchard Park, NY). The left femoral
artery and vein were catheterized to record arterial blood pressure and to allow for anesthetic, fluid
replacement, and pharmacological agent delivery, respectively. The right femoral artery was
catheterized and left ventricular pressure was measured via a Mikro-Tip Pressure Transducer
Catheter (Millar Instruments, Houston, TX). Heart rate was monitored via a Lead II
electrocardiogram.
Spinal cord stimulation (SCS): For the SCS treatment group, each animal was placed in the prone
position and the spinal epidural space was penetrated percutaneously with a Touhy needle through a
small skin incision in the caudal dorsal thorax as detailed previously (4). An eight-pole lead (Octrode,
Advanced Neuromodulation Systems, Plano, TX) was advanced rostrally in the epidural space to the
T1-T3 spinal cord level. The tip of the lead was positioned slightly to the left of midline using
anterior-posterior fluoroscopy. The rostral pole was positioned at T1 while the caudal pole was
positioned at T3 level. Proper electrode placement was determined via electrical current delivered to
the rostral and caudal poles using a stimulus isolation unit and constant current generator (PSIU6,
Grass Instruments, Quincy, MA) connected to a stimulator (S88, Grass Instruments, Quincy, MA).
SCS was delivered at 50 Hz and 200 μs duration, stimulus parameters that have previously been
shown to induce neuromodulation of extracardiac intrathoracic and intrinsic cardiac ganglia neurons
during periods of acute cardiac stress (4; 13). Motor threshold (MT) intensity was determined as the
lowest current that induced muscle contractions in the proximal forepaw and shoulder. Animals
were rotated to the supine position for the experimental protocols with MT rechecked in this
position. MT was checked periodically during the experiments and did not vary significantly from
initial levels (0.25±0.02 mAmp).
84

Mediastinal nerve stimulation - MSNS: Following thoracotomy, an incision was made into the pericardial
sac and a pericardial cradle formed. A bipolar electrode was affixed to the right atrium, 1 cm dorsal
to the SA node to record atrial electrograms. Right-sided mediastinal nerves were identified visually
on the ventral and ventro-lateral surface of the intrapericardial aspects of the superior vena cava and
then stimulated using techniques detailed elsewhere (9; 28). Briefly, trains of five electrical stimuli
(0.3-1.2 mA, 1 ms duration, 5 ms pulse interval) were delivered for up to 20 seconds to select
mediastinal sites during the refractory period on each atrial beat, as triggered off the reference atrial
electrogram. This was done to avoid direct atrial capture. Electrical stimuli were delivered via a
roving bipolar probe electrode (1.5 mm spacing) connected to a constant current generator (PSIU6,
Grass Instruments, Quincy, MA) affixed to a Grass S88 stimulator (S88, Grass Instruments, Quincy,
MA). The stimulator was externally controlled by a computer running LabChart5 (ADInstruments,
Colorado Springs, CO) interfacing with a Powerlab 4/30 (ADInstruments, Colorado Springs, CO)
and triggered by atrial wavefront detections. Active sites were identified by the creation of atrial
tachyarrhythmias (including atrial fibrillation) when exposed to focal electrical stimuli. Each active
site was marked with India ink for repeat stimulation. Two to four active sites were identified in each
animal. Contact between the bipolar electrodes and tissue was discontinued immediately after the
onset of the atrial tachyarrhythmia.
Neuronal Recording: Activity generated by neurons in the right atrial ganglionated plexus (RAGP) was
recorded in situ, as reported previously (3; 14). Briefly, to decrease epicardial motion during each
cardiac cycle, a circular ring of stiff wire was placed gently on the epicardial fat on the ventral surface
of the right atrium - a region known to contain the RAGP. A tungsten microelectrode (250 μm
diameter and exposed tip of 1 μm; impedance of 9-11 MΩ at 1000 Hz), mounted on a
micromanipulator, was lowered into this fat using a microdrive. The ganglionated plexus therein was
explored and electrical signals so derived were led into a differential preamplifier (BMA-831, CWE
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Inc., Ardmore, PA) with a high impedance head stage (band width set at 300 Hz to 10 kHz). Signals
were further amplified by a battery-driven pre-amplifier (5113 Pre-Amp, Signal Recovery, Oak
Ridge, TN) (band width 100 Hz to 2 kHz). Amplified neuronal signals, together with recorded
cardiovascular indices, were digitized (Cambridge Electronics Design, power 1401 data acquisition
system) and analyzed using the Spike 2 software package (Cambridge Electronics Design).
Neuronal activity was identified as action potentials with signal to noise ratios greater than 3:1. The
activity generated by individual neuronal somata was identified by the amplitude and configuration
(waveform recognition) of these recorded action potentials, using the Spike 2 program. Using these
techniques and criteria, action potentials generated by individual somata and/or dendrites, rather
than axons of passage, can be recorded for extended periods of time (3; 4; 14).
Treatment Groups: Animals were divided randomly into two neuromodulation treatment groups, one
that had SCS electrode implantation (n=16) and another that evaluated the effects of ganglionic
blockade on arrhythmia responses evoked by MSNS (n=12). For each of these animals, 2-3
mediastinal sites were first identified that reproducibly evoked atrial arrhythmias. In 8 of these
animals (4 from each group), time controls were done to verify reproducibility of evoked responses
to MSNS over time. For the SCS treatment group, electrical stimuli (50 Hz, 200 μs duration, 90%
Motor threshold) were delivered to the T1-T3 spinal level for 20 min. Responses to MSNS
stimulation were evaluated prior to and 5-30 min. following SCS. For the hexamethonium treatment
group, responses to MSNS stimulation were evaluated prior to and 15 min after hexamethonium
administration (5 mg/kg, i.v.).
Data Analysis: Action potentials arising from a site within each RAGP studied were characterized by
means of their differing amplitudes and configurations (waveform recognition via the Spike2
program: Cambridge Electronic Design, Cambridge, England CED). Neuronal activity responses
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elicited by MSNS were evaluated by comparing activity generated immediately before stimulation
with data obtained during nerve stimulation; neuronal activity data are presented as impulses per
second (imp/sec). Characterization of atrial rhythms evoked by MSNS included latency and duration
of atrial arrhythmias; this analysis was performed offline using Spike 2. Data are expressed as means
± SEM. Sigmastat 3.1 (Systat software) was used to test for differences between groups by ANOVA
with post-hoc comparisons (Holm-Sidak or Tukey method for comparisons, depending on results of
normality tests). A significance of p< 0.05 was used for these experiments.
Results:
Neuroanatomical data: Select mediastinal nerve projections to the right atrial ganglionated plexus were
identified that, when subjected to trains of focal electrical stimuli delivered during the atrial
refractory period, reproducibly induce transient periods of atrial fibrillation. DiI was then microinjected into the wall of the superior vena cava at that nerve site. RAGP tissues harvested 2 days
after application of Dil to that mediastinal nerve site identified 13.2% of RAGP neuronal soma
labeled. PGP 9.5 (green) labeled all neuron soma in these RAGP. Some neuronal somata
demonstrated co-localization of PGP 9.5 and Dil (Fig. 1). The neurochemical profile of Dil labeled
neurons within these RAGP demonstrated that 16.7% of Dil labeled neurons also labeled for
cholinergic marker choline acetyltransferase (ChAT) (Fig. 2). 22.2% of Dil labeled neurons labeled
for the noradrenergic marker tyrosine hydroxylase (TH); 55.6% of Dil labeled neurons co-localized
with markers for ChAT and TH. The remaining 5.5% of Dil labeled neurons did not exhibit either
noradrenergic or cholinergic markers.
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Figure 1. Characterization of neuronal cell bodies in the RAGP, labeled with the tracer (Dil)
injected into right-sided mediastinal nerve sites where electrical stimulation (MSNS) induced AF.
PGP 9.5 labeled all intrinsic cardiac neurons (ICN) green and DiI labeled neurons projecting from
MSNS responsive sites in red. Co-localization of PGP 9.5 and DiI is indicated by yellow (arrows
indicate double-labeled soma) in the overlap figure (OVL). 13.2% of PGP 9.5 labeled neurons
within the RAGP co-localized with Dil. Scale bar equals 75 um.
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Figure 2. Neurochemical profile of RAGP neurons labeled with the tracer (Dil) injected into rightsided mediastinal nerve sites where electrical stimulation (MSNS) induced AF. Neurons were
immunolabeled for choline acetyltransferase (ChAT; green label), tyrosine hydroxylase (TH; blue
label) and DiI (red label). Solid arrow indicates co-localization of ChAT and DiI (16.7% of neurons).
Open arrow indicates co-localization of TH and DiI (22% of neurons). Open arrowheads indicate
co-localization of DiI with both ChAT and TH (55.6% of neurons). Solid arrowhead indicates a DiI
neuron that did not label with either TH or ChAT markers (5.5% of neurons). Scale bar equals 40
um.
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Intrinsic Cardiac Neuronal Activity: The activity generated by RAGP neurons increased in response to
MSNS (Fig. 3). Mediastinal nerve stimuli induced an initial bradycardia (average 23.7±3.5% change
from baseline cycle length) that transitioned rapidly to atrial fibrillation/flutter (AF/AFl). The
average latency of such responses was 1.3±0.2 sec. from stimulus onset; the average duration of
AF/AFl was 26.4±6.0 sec. Intrinsic cardiac neuronal activity increased in association with stimulus
onset; neuronal activity increased further during the induction of AF. This enhancement of activity
persisted during the initial period following sinus rhythm restoration (Fig. 3). On average, MSNS
evoked ~4 fold increase in neuronal activity (Fig. 5, left panels; 0.29±0.08 imp/s to 1.20±.16
imp/sec, p<0.001).

Figure 3. RAGP neuronal activity and corresponding cardiac electrical activity in response to
MSNS. Arrows indicate delivery of 4 successive burst stimuli to a right-sided mediastinal nerve
located on the SVC at the level of the pericardial reflection. MSNS induced an increase in RAGP
neuronal activity, which persisted after stimulus cessation. Neuronal activity was further enhanced
once the arrhythmia was induced. Vent. – ventricle, RAGP activity – right atrial ganglionated plexus
neuronal activity Trace three (activity in impulses per second) indicates ongoing 1 sec bin summed
activities. Note that during burst stimuli heart rate was reduced from 83 to 76 bpm immediately
prior to initiation of atrial fibrillation. Insert shows expanded trace for one of RAGP neurons
recorded.
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Neuronal responses evoked by MSNS were altered by both pre-emptive SCS and nicotinic receptor
blockade. While, SCS did not decrease basal neuronal activity (Fig 4 and Fig 5 top panel; 0.27±0.10
imp/sec versus 0.22±0.10 imp/sec), MSNS-induced changes in RAGP activity was suppressed
significantly after 20 min. of pre-emptive SCS (1.19±0.17 to 0.68±0.18 imp/sec, p<0.001) (Fig. 5,
top panel). Hexamethonium administration likewise did not affect basal neuronal activity (Fig. 5,
bottom), yet completely suppressed the MSNS-evoked increase in RAGP neuronal activity
(0.38±0.20 to 0.55±0.19 imp/sec; p=.143) (Fig. 5, bottom panel).

Figure 4. Neuronal activity recorded from the same RAGP site depicted in Fig. 3 demonstrating the
effects of MSNS repeated 5 min after 20 min pre-emptive SCS. Note that following SCS, MSNS was
ineffectual in evoking atrial arrhythmias.
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Figure 5: Effects of
MSNS on RAGP
neuronal activity recorded
prior to and following
pre-emptive SCS (top
panel) or hexamethonium
administration (bottom
panel). MSNS initiated a
~4 fold increase in
neuronal activity. Preemptive SCS blunted the
ability of MSNS to
increase neuronal activity.
Hexamethonium blocked
MSNS evoked increase in
neuronal activity. *
p<.002 versus baseline; +
p<.001 versus control.

MSNS-induced bradycardia: Figure 6 summarizes the effects of hexamethonium (top panel) or preemptive SCS (bottom panel) on the magnitude of the initial MSNS-evoked bradycardia. In the
hexamethonium treated group, while basal cardiac cycle length increased (454.3±16.6 versus
507.9±20.5 ms, p=.009), the absolute MSNS-evoked bradycardia was similar over time (535.6±16.3
versus 540.1±20.5 ms, p=.78). Moreover, even following nicotinic receptor blockade, MSNS
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continued to increase cardiac cycle length (507.9±23.8 baseline to 540.1±20.5 MSNS, p<.001), albeit
at a lesser magnitude compared to control. In contrast, pre-emptive SCS did not affect the MSNSevoked bradycardia (23.7±3.5%: 433.6±11.4 to 532.0±11.9 ms, p<0.001).
Figure 6. Mediastinal
nerve stimulation-induced
an initial atrial bradycardia
before and following
hexamethonium
administration (top panel)
or pre-emptive SCS
(bottom panel). * p<.001
versus basal; + p<.01
versus control.

Time controls: Time controls for both treatment groups exhibited similar MSNS evoked changes in
RAGP neuronal activity (0.21±0.05 to 1.00±.40 imp/sec versus 0.15±0.04 to 1.02±.11 imp/sec,
basal to MSNS). Time controls also demonstrated consistent responses in basal cycle length
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(420.3±9.6 ms versus 415.8±7.9 ms, p=.99) and equivalent evoked changes in cardiac cycle length
with MSNS onset (526.1±22.2 ms versus 507.3±20.9ms; p=0.70).
Atrial Rhythms: Atrial rhythm responses to MSNS were studied before (panel A: control 94 active
sites) and following either hexamethonium administration (panel B: 28 of the 94 sites) or preemptive SCS (panel C: 66 of the 94 sites). In control states, the predominant atrial rhythm evoked by
right-sided MSNS was AF/AFl (77.7%); sinus bradycardia (12.8%), sinus tachycardia (4.2%), and
other rhythms (5.3%) were induced less frequently. Time controls demonstrated no significant
change in these response characteristics. Following ganglionic blockade, MSNS evoked AF/AFl
from only 7.1% of the nerve sites stimulated (Fig. 7, panel B); sinus rhythm/bradycardia was the
predominant rhythm (82.2% of sites).
Figure 7. Types of atrial
rhythms evoked during
mediastinal nerve stimulation
prior to (A, control) and
following treatment with
hexamethonium (panel B) or
pre-emptive T1-T3 SCS (panel
C). The number of stimulation
sites in each group is indicated
above each chart; the number
of arrhythmias elicited in each
subgrouping are also indicated.
AF/AFL – atrial
fibrillation/atrial flutter.
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Following pre-emptive SCS, the predominant atrial rhythm evoked by MSNS shifted to sinus
bradycardia (56.2%). Not only did pre-emptive SCS reduce the number of mediastinal sites that
evoked AF (77.7% to 33.3%, Fig. 7), but for the residual active sites the latency to evoke such AF
increased (1.03±0.12 to 1.63±0.20 sec; p=.004) and duration of such evoked AF decreased
(33.8±9.9 to 14.8±3.0 sec; p=.047) (Fig. 8). Time controls exhibited no change in the latency to AF
onset (1.26±0.29 to 1.15±0.25 sec; ns) or the duration of MSNS-evoked AF (21.5±13.9 to 22.6±6.8
sec; n.s.).
Figure 8. SCS-induced
changes in AF
characteristics in SCSresistant stimulation sites.
Even when atrial fibrillation
persisted from 22 sites
following pre-emptive SCS,
its latency increased and
duration decreased. * p<.05
from control.
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Discussion:
Excessive inputs to the intrinsic cardiac nervous system via, for instance, activating select
mediastinal nerve inputs to that system, are known to initiate ectopic atrial activation that can lead to
alterations in atrial rhythms (9; 10 28). As such, it has been proposed that selective activation of
inputs to the ICN leads to excessive and heterogeneous activation within that nervous system to
induce atrial arrhythmias (9).
In fact, select neuronal receptors (specifically nicotinic and α-adrenergic ones) have been implicated
in mediating neuronally-induced atrial arrhythmias (9; 28). In agreement with that concept, systemic
administration of hexamethonium or α-adrenergic receptor blocking agent obtunds the ability of
MSNS to generate atrial dysrhythmias (9; 28). In addition to such pharmacological neuromodulation,
neuromodulation involving electrical stimulation of the dorsal, thoracic spinal cord can similarly
decrease the ability of the intrinsic cardiac nervous system to generate atrial arrhythmias when
excessively activated (10). While previous studies have inferred the involvement of specific
subpopulations of intrinsic cardiac neurons in neural mechanisms associated with atrial arrhythmias,
this study demonstrates the specifics of the neural-substrate so involved and the potential to target it
therapeutically to manage atrial arrhythmias.
The ICN has been traditionally thought to represent a simple relay station for parasympathetic
efferent innervation of the heart (21). However, recent research has altered this view by elucidating
the presence of a variety of intrinsic cardiac neurochemical phenotypes in conjunction with different
functional classes of neurons including afferent, efferent and local circuit neurons that interact
reflexly to modulation regional cardiac electrical and mechanical activities (6; 16; 26). Most intrinsic
cardiac neurons display immunoreactivity to cholinergic markers, some without cholinergic inputs
(18). Other intrinsic cardiac neurons, including human intrinsic cardiac ganglia, express an
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adrenergic phenotype (17; 18; 32). Moreover, various of these neurons are also innervated by
peptidergic, nitrergic, and noradrenergic fibers (16; 18; 29). In accord with such anatomy, in this
study immunohistochemistry analysis demonstrated that the populations of ICN neuronal somata
receiving inputs from mediastinal nerves that induce arrhythmogenic activity express cholinergic
and/or adrenergic markers. In addition, there is another population of intrinsic cardiac neurons that
appear to be involved in the genesis of atrial tachyarrhythmias that are neither cholinergic nor
adrenergic in function.
It has been reported that the largest population of intrinsic cardiac neurons, represented by local
circuit neurons, has the ability to process afferent and efferent inputs, thereby contributing to
efferent neuronal control over regional cardiac function (6). As such, this population receives not
only cardiac sensory inputs (3) but also efferent inputs from both limbs of the autonomic nervous
system (8; 14). The integration of afferent and efferent inputs, combined with the capacity of
intrinsic cardiac local circuit neurons to interact with neurons within other intrathoracic ganglia,
comprises organ-level neuronal processing for functional control (7; 15; 34; 36).
The present study demonstrates that MSN activation in the induction of atrial arrhythmias is
associated with alterations in the activity generated by populations of intrinsic cardiac neurons that
represent different phenotypical subtypes (Fig. 3). Furthermore, these data demonstrate that
excessive inputs to the ICN can indeed result in activation of neuronal populations therein – such
neurons responding with activity rates considerably above control levels. As such, these data
confirm the fact that atrial electrical instability can be related to excessive activation of select
populations of ICN neurons. When synaptic efficacy within the ICN is compromised by nicotinic
blockade, this arrhythmogenic potential is reduced in response to nerve imbalances within the
cardiac nervous system. However, such ganglionic blockade is associated with major deficits in
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efferent outflow to the periphery (33). On the other hand, SCS apparently imparts an obtunding
effect on such excessive excitation of intrinsic cardiac neurons such that in many instances excessive
mediastinal nerve inputs failed to enhance intrinsic cardiac neuronal activity (Fig. 4). Yet efferent
function to the heart is maintained following SCS (Fig. 6). This, in turn, may explain why SCS
appears to influence cardiac indices (12; 23), albeit in a relatively minor fashion (13; 20). It does so
by restraining reflex pathways within intrathoracic autonomic ganglia associated with cardiac control
(4; 13). SCS likewise does not blunt the chronotropic or dromotropic responses associated with
extracardiac stimulation of principal parasympathetic or sympathetic projections to the heart (25).
On the other hand, the reduction in ICN neuronal activation induced by excessive mediastinal nerve
inputs presumably was the result of SCS modulation/suppression of local circuit neurons, c.f. figure
3. In fact, that population represents the largest target population within the ICN (8; 14). That such
neuronal responsiveness to excessive inputs was obtunded is further demonstrated by the fact that
more than half of previously responsive neurons identified were no longer activated by MSNS
following SCS.
Perspectives and Significance: It is becoming apparent that neuronal control of the heart is significantly
more complex than previously thought (6). Multiple tiers of neuronal processing occur within the
cardiac neuronal hierarchy that ultimately acts to coordinate neuronal inputs to the heart (4; 7; 13).
Stresses, either pathological or physiological, may disrupt the balance of efferent neuronal inputs
that can lead to altered cardiac function (6; 22). As such, novel therapies that overcome any such
imbalance in cardiac control, as represented by neuromodulation of the ICN via SCS, may moderate
excessive activation of the ICN in response to transduction of pathological cardiac stressors. Other
electrical neuromodulation-based therapies, such as low-level vagosympathetic stimulation, may
target peripheral aspects of the cardiac nervous system to reduce the arrhythmogenic potential (31;
35), but their respective neuronal targets have yet to be established (2).
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Indeed, data derived from this study indicate that SCS can 1) stabilize intrinsic cardiac local circuit
neurons in the presence of excessive extracardiac inputs, thereby obtunding any capacity to induce
atrial arrhythmias and 2) do so without affecting direct autonomic efferent neuronal outflows to the
heart to compromise cardiac function. In contrast, nicotinic receptor blockade suppressed not only
the capacity of local circuit neurons to become excited but also autonomic efferent projections that
influence cardiac indices. Such data delineate the possibility of targeting local as opposed to central
derived inputs to the heart. They also support the thesis that SCS may represent a novel therapeutic
strategy to counteract pathologically-induced excessive activation of the ICN that would otherwise
lead to atrial arrhythmia induction.
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CHAPTER 5
Summary
Chapter 2 determined that cervical SCS decreased infarct size resulting from MI by using
dorsal spinal column projections to modify adrenergic efferent functions. Dorsal column
transection or adrenergic receptor blockade eliminated the infarct size reduction effect of cervical
SCS. Cervical SCS also decreased the activation of spinal cord neurons in laminae I-V that resulted
from MI. In the presence of cervical SCS, β-adrenergic blockade and cervical vagal transection
eliminated the incidence of SCD while muscarinic blockade had no effect. The data presented
indicate that cervical SCSC utilizes both adrenergic and cholinergic efferent mechanisms to stabilize
cardiomyocytes and the arrhythmogenic potential in response to ischemic stress.
Chapter 3 found that cardiac primary afferent neurons in the nodose and DRG were
activated by transient myocardial ischemia. High thoracic SCS did not directly activate cardiac
primary afferent neurons in the DRG or nodose, yet it did mitigate the MI-induced increase in
cardiac primary afferent neuronal activity in both afferent populations. Our data indicate that preemptive SCS exerts this effect by altering the sensory milieu of the stressed heart rather than by
direct antidromic activation of primary afferent fibers.
Chapter 4 demonstrated that intrinsic cardiac neurons have numerous distinct
neurochemical phenotypes including adrenergic, cholinergic, adrenergic/cholinergic, and nonadrenergic/non-adrenergic phenotypes. MSNS activated distinct subpopulations of intrinsic cardiac
neurons within associated periods of AF. Neuromodulation therapy, exerted by thoracic SCS or
hexamethonium, decreased the activation of the intrinsic cardiac neurons resulting from MSNS and
stabilized the atrial arrhythmogenic substrate. The stabilization effects on AF induction of
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hexamethonium were greater than those of thoracic SCS. Our data indicate that hexamethonium
targets efferent and local circuit neurons while SCS preferentially modulates local circuit neurons.

Organization of the Cardiac Nervous System for Control of Normal and Stressed Hearts
The cardiac nervous system consists of afferent, efferent, and local circuit neurons that
interact to control heart function (Armour 1999; 2004). Cardiac-related afferent neurons transmit
sensory signals (mechanosensory and/or chemosensory) via the DRG to the spinal cord for
sympathetic afferents and via nodose ganglia to the brainstem for parasympathetic afferents
(Armour 1999; 2004; Cheng and others 1999; Hopkins and Armour 1984; Marieb 2004). For
control of cardiac sympathetic function, brainstem cardiovascular-related centers send projections
down to the thoracic spinal cord to the intermediolateral cell column (origin of sympathetic preganglionic neurons)with subsequent projections from these neurons to the
intrathoracic/extracardiac ganglia (Marieb 2004). These ganglia, in turn, send efferent sympathetic
postganglionic projections to the heart (Marieb 2004). Parasympathetic efferent pathways travel
from the brainstem through the vagi to the heart making the pre- to post-ganglionic connections at
the intrinsic cardiac ganglia (Armour 1999; 2004; Cheng and others 1999; Hopkins and Armour
1984; Marieb 2004). Contained within each of the autonomic ganglia of the cardiac nervous system
are local circuit neurons that serve to connect afferent and efferent neurons within single ganglia and
between different intrathoracic ganglia (Armour 2008). The cardiac nervous system is organized in a
series of nested feedback control loops (Armour 1999; 2004; 2008). The most basic of these
networks is the intrinsic cardiac nervous system, which is composed of numerous ganglia on the
heart itself and serve to control regional cardiac function on a beat-to-beat basis (Armour 1999;
2004; 2008). Expanding outward from the intrinsic cardiac nervous system are the reflex control
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networks contained within the intrathoracic “sympathetic” ganglia, with subsequent nodes for reflex
processing contained within the spinal cord and brainstem (Armour 1999; 2004; 2008). Higher
centers of the brain can adjust cardiac control by modulating the cardiac nervous system, e.g. fight
or flight, automatic response to pain, etc. (Marieb 2004). Neural interactions between various levels
of the cardiac nervous system allow for effective coordination of cardiac function at rest and during
periods of cardiac stress (Armour 1999; 2004; 2008). Included in these network interactions are
propriospinal pathways within the spinal cord that allow for communication between spinal cord
segments with the high cervical cord exerting major modulating effects on thoracic and lumbar
reflex processing of organ specific functions (Chandler and others 1996; Ding and others 2008b;
Foreman 1999; Marieb 2004).
Research into numerous cardiac pathologies has elucidated characteristics of the cardiac
nervous system and how it remodels during such stress (Cardinal and others 2004; Eliasson and
others 1996; Mannheimer and others 1998; Southerland and others 2007). One of those cardiac
pathologies, MI, causes referred pain that is sensed in the arm or neck (Foreman 1999). Those areas
are part of the upper cervical somatic dermatomes, sections of the surface of the body whose
sensory information enters the spinal cord at specific levels (Foreman 1999). C1-C3 cervical spinal
cord segments also receive parasympathetic and sympathetic afferent inputs, arising from both
intrathoracic and visceral organs (Chandler and others 1996; Chandler and others 2000; Ding and
others 2008a; Ding and others 2008b; Foreman 1999; Qin and others 2007a; Qin and others 2008;
Qin and others 2004; Qin and others 2007b). These findings led to the theory that the upper
cervical spinal cord functions as a coordinating and processing center for sensory information
passing up the spinal cord (Ding and others 2008a; Ding and others 2008b; Foreman 1999; Qin and
others 2008). The upper cervical region of the cord likewise uses intersegmental interconnections to
interact with other levels of the cord (Qin and others 2007b). As such, targeting the upper cervical
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region with electrical neuromodulation has the potential to modulate reflex control of visceral
functions including the heart (Ding and others 2008b; Qin and others 2007a; Qin and others 2008).
Neuromodulation as a Therapeutic Approach for Control of Cardiac Nervous System and Heart
The first experiments to study how SCS affects the cardiac response to MI focused on the
spinal segments where the cardiac afferent- and efferent-related pathways enter and exit the spinal
cord (Hua and others 2004b; Qin and others 2008) These clinical studies focused on retractable
angina pectoris as the disease state to which SCS may have therapeutic benefits (Eliasson and others
1996; Mannheimer and others 1993). The results of those studies indicated that thoracic SCS
decreased anginal pain symptoms, increased exercise tolerance, and delayed the onset of anginal
symptoms(Eliasson and others 1996; Mannheimer and others 1993) . These clinical observations
prompted subsequent basic science research into how SCS exerted its anti-anginal effects (Cardinal
and others 2006; Foreman and others 2000; Southerland and others 2007).
Basic science studies have elucidated that thoracic SCS decreases intrinsic cardiac and
extracardiac sympathetic neuronal reflex activation in response to MI stress and, if initiated preemptively, decreases the infarct size resulting from MI (Ardell and others 2009; Foreman and others
2000; Southerland and others 2007). SCS does so without changing blood flow through coronary
vessels at rest or during ischemic stress or by changing pressure-volume ratio within the left ventricle
(Ardell and others 2009; Kingma and others 2001). Transection of the ansae subclavian,
interruption of afferent and efferent interconnections between the spinal cord and peripheral aspects
of the cardiac nervous system, eliminates the cardioprotective effects of thoracic SCS (Cardinal and
others 2006; Foreman and others 2000). These data suggest that the SCS-induced effects are
mediated by changing neural activity within the cardiac nervous system (Armour 1999; 2004; 2008).
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In this regard, SCS has demonstrated efficacy to modify neural processing in multiple levels
of the cardiac nervous system hierarchy and the effects are long-lived (Armour 1999; 2004; 2008).
Thoracic SCS decreases the cardiac nociception transduction in dorsal laminae (I-V) of the spinal
cord, a response that affects not only evoked components of cardiac pain but also induced changes
in autonomic functions (Ardell and others 2009; Qin and others 2008). MI causes the release of
several chemicals including bradykinin and adenosine into the milieu of the heart (Armour 1999;
Herring and Paterson 2009). Exogeneous application of those chemicals can therefore be used to
mimic the effects of acute MI (Chandler and others 2000; Gnecchi-Ruscone and others 1995; Huang
and others 1996). Research shows that SCS can modulate the effects of MI by decreasing the
responsiveness of the cardiac nervous system to those “algogenic” chemicals (Qin and others 2008).
The exact nature of the mechanism through which SCS can decrease the responsiveness of the
cardiac nervous system and therefore decrease the detrimental effects of MI remains to be
determined (Armour 1999; 2004; 2008).
Cardiac stress impacts cardiac electrical and mechanical function and the neurohumoral
systems that modulates it (Armour 1999; 2004). SCS reduces electrically-induced arrhythmia
formation and naturally-occurring arrhythmias (Cardinal and others 2006; Issa and others 2005;
Lopshire and others 2009; Zipes 2008). For example, SCS has been shown to reduce the atrial
arrhythmogenic potential arising from induced neural imbalance within the cardiac nervous system
(Cardinal and others 2006). Thoracic SCS also decreased the incidence of ventricular arrhythmia
formation in response to transient ischemia following rapid ventricular pacing in an animal model
with a previous ischemic injury (Issa and others 2005; Lopshire and others 2009). Finally, SCS
improves cardiac contractile function during recovery from experimentally-induced heart failure
(Lopshire and others 2009). Together, these data demonstrate the overall efficacy of SCS to mitigate
adverse consequences of cardiac stress.
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In addition to impacting the cardiac nervous system, SCS also exerts cardioprotective effects,
in part, by modulating cardiomyocytes and their response to stress (Ardell and others 2010;
Southerland and others 2007). SCS activates intracellular signaling pathways, such as protein kinase
C (PKC) (Ardell and others 2010; Southerland and others 2007). Activating PKC pathways is a
major mediator in preconditioning the heart to reduce the effects of ischemia (Sanada and Kitakaze
2004; Yellon and Downey 2003). These mechanisms serve to protect the myocardium from the
insult of MI (Ardell and others 2010; Sanada and Kitakaze 2004; Southerland and others 2007;
Yellon and Downey 2003). The specifics of how SCS-induced cardioprotection is imparted on
neural and myocyte function is the central focus of this dissertation.
Neuromodulation of the Ischemic Heart
SCS Effects on Afferent Transduction
One theory for the mechanism of action of SCS is that SCS directly activates afferent
neurons causing them to act in an efferent fashion. The theory of afferent neurons acting as
efferents was put forth based on data that SCS-mediated antidromic activation of afferent neurons
causes the release of neuropeptides in the periphery that induce vasodilation (Horsch and others
2004; Lembeck and Holzer 1979; Linderoth and others 1994; Tanaka and others 2003; White and
Helme 1985). This vasodilation, in turn, salvaged ischemic tissue in a skin flap preparation
(Linderoth and others 1991; Tanaka and others 2003). While antidromic activation of afferent fibers
accounts for peripheral vasodilation for cutaneous tissues, Chapter 3 indicates that SCS does not
antidromically activate primary cardiac-related afferent neurons (Gherardini and others 1999;
Horsch and others 2004). These data point to a different mechanism. Clinical studies put forth the
hypothesis that SCS-induced anti-anginal effects by altering supply/demand balance (Linderoth and
Foreman 1999). However, subsequent research has demonstrated that thoracic SCS does not induce
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coronary blood flow changes, at least in a normal heart, and has minimal effects on pressure-volume
characteristics of the normal or ischemia-stressed heart (Kingma and others 2001). Yet, SCS does
blunt MI-induced activation of dorsal column neurons receiving inputs from cardiac nociceptors
(Ding and others 2008a; Ding and others 2008b). Based on the studies outlined in Chapter 3, we
propose the hypothesis that pre-emptive thoracic SCS modifies the milieu of the heart arising in
response to stress which secondarily alters the sensory transduction of cardiac stress (Armour 2008).
That is to say, pre-emptive SCS renders cardiomyocytes ischemic-resistant and thereby mitigates the
MI-induced release of metabolites that activate the cardiac nociceptors.
SCS Effects on Infarct Size
While thoracic neuromodulation induces cardioprotective effects, it remained to be
determined if cervical SCS exerts cardioprotection against the effects of acute MI (Southerland and
others 2007). Previous studies showed that pre-emptive thoracic SCS decreased infarct size in
response to transient MI (Southerland and others 2007). Previous work also demonstrated that high
cervical spinal segments modified neural activity in thoracic and lumbar regions of the spinal cord
arising from peripheral organs (Ding and others 2008a; Ding and others 2008b; Qin and others
2007a; Qin and others 2008; Qin and others 2007b). Several mechanisms of the potential
cardioprotective effects of high cervical SCS were investigated in this dissertation, including the role
of spinal cord segmental and supraspinal interconnections and their role in modifying adrenergic and
cholinergic efferent functions.
Intersegmental communication underlies the ability of high cervical SCS to exert
cardioprotective effects. This requirement of intersegmental communication was demonstrated by
how C6 cervical dorsal column transection eliminated that cardioprotection. Chapter 2 determined
for the first time that communication between the cervical and thoracic spinal segments is necessary
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for cervical SCS to exert its cardioprotective effects (Hua and others 2004a; Hua and others 2004b;
Qin and others 2004b; Qin and others 2007b). These data indicate that the upper cervical spinal
segments may in fact function as a coordinating center for lower spinal cord reflex function with
respect to the cardiac nervous system (Ding and others 2008a; Ding and others 2008b; Qin and
others 2007a; Qin and others 2008; Qin and others 2007b).
High cervical neuromodulation uses peripheral ganglia of the cardiac nervous system to
induce its cardioprotective effects. Previous research indicates that intrinsic cardiac ganglia contain
adrenergic and cholinergic efferents, a fact that Chapter 4 corroborates (Armour 1997; Hoard and
others 2008; Hoover and others 2009; Singh and others 1999). Data presented in Chapter 2
demonstrate that selective blockade of adrenergic receptors or the cholinergic muscarinic receptors
differentially modifies the ability of C1-C2 SCS to mitigate the MI-induced changes in myocyte
viability in response to transient MI. The fact that cervical vagotomy, in contradistinction to
atropine, produced no change in the ability of SCS to protect myocytes is likely reflective of the
reflex processing that remains in the peripheral aspect of the cardiac nervous system, even when
surgically disconnected from higher centers (Ardell and others 1991; Armour 2008; Armour and
others 2005).
Previous work has indicated the predominant role of SCS-induced changes in sympathetic
reflex function in mediating overall cardioprotection (Armour 1997; Armour and others 2005;
Richer and others 2008). The ability of selective adrenergic blockade to eliminate the cardiomyocyte
protective effects of SCS in response to MI substantiates that SCS exerts its effects via modulation
of adrenergic function using both α- and β-dependent receptors (Southerland and others 2007).
This adrenergic mediation of SCS cardioprotective effects is substantiated by previous research
where surgical disruption of the sympathetic afferent/efferent pathways, via transection of the ansae

112

subclavian, eliminates the protective effects of SCS (Cardinal and others 2006; Foreman and others
2000). The fact that intrinsic cardiac neurons, of which a large population is local circuit, also
contain adrenergic receptors suggests that SCS mediates its cardiomyocyte protective effects, in part,
through modifying neural subtypes at both intracardiac and extracardiac ganglia, as well as at the end
effectors of the heart (Armour 2008; Armour and others 2002; Cardinal and others 2006; Foreman
and others 2000; Southerland and others 2007). Chapter 4 indicates that SCS preferentially modifies
local circuit neuronal activity without affecting efferent outflow to the heart. Together, these
findings implicate the local circuit neurons, which are contained throughout the cardiac nervous
system, in mediating, in part, the cardiomyocyte protective effects of SCS (Armour 2008).
In addition to modulation of reflex function within the cardiac nervous system, SCS also
modulates myocyte function (Southerland and others 2007). For example, SCS-induced activation
of the protein kinase C pathways contributes to the infarct reduction associated with pre-emptive
SCS (Southerland and others 2007). Other intracellular signaling pathways such as α-adrenoceptor
coupled PKC pathways and β-adrenoceptor coupled PKA and p38 MAPK pathways, when
activated can also reduce the lethal effects of MI on cardiomyocytes (Sanada and Kitakaze 2004;
Tsuchida and others 1994; Yellon and Downey 2003). The fact that both α- and β-receptor
blockade blunted SCS-induced reduction in infarct size substantiates this hypothesis.
The ability of pre-emptive SCS to impact the cardiac myocytes is also demonstrated by the
modification of the contractility response to acute MI. While SCS has no discernible effects on
gross hemodynamics during unstressed states, left ventricular function was significantly improved
during transient MI when done in the presence of SCS (Foreman and others 2000; Kingma and
others 2001; Southerland and others 2007). It remains to be determined if this effect is produced by
induced changes in neural reflex processing in response to transient MI or if the myocytes are
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rendered ischemia-resistant by pre-emptive SCS (Kingma and others 2001; Sanada and Kitakaze
2004; Tsuchida and others 1994; Yellon and Downey 2003).

SCS and the Potential for Ischemia-Induced SCD
MI-induced changes in cardiac electrical stability involve both intrinsic and extrinsic factors
(Armour 1999). Intrinsic effects include alterations in cardiac conduction and induction of ectopic
pacemakers (Armour 1999). Extrinsic factors include alterations in autonomic reflex control
involving both parasympathetic and sympathetic efferent projections (Armour 1999; 2004). Without
SCS, atropine evoked minimal changes on the potential for MI-induced ventricular fibrillation.
Following vagotomy, the potential for MI-induced ventricular fibrillation increased. This is in
agreement with previous studies where increased parasympathetic efferent outflow to the heart has
anti-arrhythmogenic effects (Schultz 2001; Vanoli and others 2008). By inference therefore, the
elimination of all centrally-derived parasympathetic efferent outflow should result in the emergence
of an exaggerated sympathetic efferent reflex response to MI, an effect that would increase lethal
arrhythmia formation (Chen and others 2001; Schwartz 2001). With high cervical SCS, atropine
moderately increased the potential for MI-induced ventricular fibrillation; but cervical vagotomy
prevented it. The elimination of lethal arrhythmia formation from cervical vagotomy in the
presence of MI and SCS likely reflects the reduction in heterogeneity of autonomic inputs to the
heart coupled with neurally- (sympathetic) induced stabilization of the intrinsic cardiac neuronal
reflex processing (Armour and others 2002; Foreman and others 2000; Huang and others 1993).
These data support the theory that SCS-induced stabilization of the cardiac nervous system is
fundamental to the anti-arrhythmic effects of SCS (Zipes 2008). These data further indicate that the
level of SCS influences the involvement of sympathetic versus parasympathetic efferent activity so
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modulated. Cervical SCS moderation of cardiac electrical function involves both branches of the
autonomic nervous system. Thoracic SCS primarily involves changes in efferent function in
extrinsic sympathetic and intrinsic cardiac neural systems.

Neuromodulation of arrhythmias
Arrhythmia formation can result from excessive neuronal input to the intrinsic cardiac
nervous system (Armour 2004; Armour and others 2005; Cardinal and others 2006; Richer and
others 2008). As demonstrated in Chapter 4, excessive neuronal input to the intrinsic cardiac
nervous system alters the activity patterns of the intrinsic cardiac neurons (Armour and others 2005).
Global suppression of peripheral autonomic ganglia activity with hexamethonium blunts both the
neurally evoked response to MSNS and the potential for induction of atrial arrhythmias. However,
such a therapeutic approach has limited applicability due to its consequent effect on overall
cardiovascular control (Armour and others 2005; Miyazaki and others 1989; Randall and others
1988). Electrical neuromodulation approach has the potential to evoke more discrete alterations in
local reflex function without compromising overall cardiovascular control (Armour 2008). For
example, modulation of intrinsic cardiac neurons, through blocking either adrenergic or cholinergic
receptors, modifies the potential for formation of arrhythmias (Armour and others 2005; Richer and
others 2008). We suggest that adrenergic/cholinergic receptor-mediated stabilizing effect to induced
nerve imbalances reflects modulation of neural processing within the intrinsic cardiac nervous
system. In support of this hypothesis, Chapter 4 indicates that SCS and hexamethonium modulate
the intrinsic cardiac neuronal response to MSNS with a corresponding decrease in the potential for
atrial arrhythmogenesis (Armour 1997; Cardinal and others 2006). Future studies should focus on
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the effects of specific receptor agonists and antagonists to modify these neuronal populations and
their response to evoked stress.
Conclusions
This dissertation has determined some of the primary neural mechanisms by which SCS
neuromodulation-based therapies induces cardioprotection in the stressed heart. The ability of SCS
at the cervical spinal segments to reduce the infarct size or potential for SCD has implications for
future uses of cervical SCS as a potential therapeutic target for treatment of ischemic heart disease.
The ability of SCS to minimize electrically-induced arrhythmia formation has implications for
effective treatment of arrhythmia formation of atrial or ventricular origin. The effects of SCS on
afferent transduction of ischemic cardiac stress demonstrate the potential of SCS to render
cardiomyocytes resistant to transient periods of MI. Together, these data indicate the effectiveness
of SCS to help maintain a state of homeostasis in the face of the destabilizing effects of cardiac
disease.
Topics for Future Study
Like all research studies, the current study has answered some questions and also elucidated
topics that need to be investigated. This is a list of some of those topics:


Investigate the effects of selective adrenergic and/or cholinergic receptor blockade on the
activity of the intrinsic cardiac neurons in response to MSNS-induced AF.



Determine how adrenergic receptor systems contribute to the actions of SCS in reducing the
reflex activation of the intrinsic cardiac neurons in response to MSNS.
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Determine the specific neurochemical phenotypes of the intrinsic cardiac neurons and how
they respond to imbalances in neural inputs, with and without SCS.



Determine the specific neurochemical phenotypes of the intrinsic cardiac neurons and how
they respond to imbalances in the stress of MI, with and without SCS.
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